Atorvastatin calcium hydrate is supported by numerous clinical trials spanning Phase I through Phase IV evaluations across completed, active, and terminated recruitment statuses. Conducted by major pharmaceutical sponsors and academic medical centers, these studies assess pharmacokinetic profiles in healthy volunteers as well as therapeutic outcomes in hypercholesterolemia, atherosclerosis, coronary artery disease, acute coronary syndrome, cerebral infarction, and diabetes mellitus.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03819101 | RECRUITING | Prostate Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2019-06-06 | PHASE3 |
| NCT03819101 | RECRUITING | Prostate Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2019-06-06 | PHASE3 |
| NCT05404139 | RECRUITING | Metastatic Prostate Cancer |
University Health Network, Toronto |
2023-05-24 | PHASE2 |
| NCT05404139 | RECRUITING | Metastatic Prostate Cancer |
University Health Network, Toronto |
2023-05-24 | PHASE2 |
| NCT07586540 | NOT_YET_RECRUITING | Carotid Stenosis |
Middle East North Africa Stroke and Interventional Neurotherapies Organization |
2027-07 | PHASE3 |
| NCT07586540 | NOT_YET_RECRUITING | Carotid Stenosis |
Middle East North Africa Stroke and Interventional Neurotherapies Organization |
2027-07 | PHASE3 |
| NCT07799779 | NOT_YET_RECRUITING | Acute Coronary Syndromes (ACS) |
Seoul National University Bundang Hospital |
2026-09 | PHASE4 |
| NCT07799779 | NOT_YET_RECRUITING | Acute Coronary Syndromes (ACS) |
Seoul National University Bundang Hospital |
2026-09 | PHASE4 |
| NCT07307989 | RECRUITING | Ischemic Stroke; Hypercholesteremia |
Chang Gung Memorial Hospital |
2025-08-01 | PHASE2 |
| NCT07307989 | RECRUITING | Ischemic Stroke; Hypercholesteremia |
Chang Gung Memorial Hospital |
2025-08-01 | PHASE2 |
| NCT07685938 | NOT_YET_RECRUITING | Chest Wall Tumor; Breast Cancer; Lung Cancer; Esophageal Cancer; Mediastinal Cancers; Spine Metastases; Spinal Tumor; Thoracic Cancer; Thoracic Neoplasms |
UNC Lineberger Comprehensive Cancer Center |
2026-08-12 | PHASE2 |
| NCT07685938 | NOT_YET_RECRUITING | Chest Wall Tumor; Breast Cancer; Lung Cancer; Esophageal Cancer; Mediastinal Cancers; Spine Metastases; Spinal Tumor; Thoracic Cancer; Thoracic Neoplasms |
UNC Lineberger Comprehensive Cancer Center |
2026-08-12 | PHASE2 |
| NCT06248671 | RECRUITING | Episodic Migraine |
St. Olavs Hospital |
2024-05-01 | PHASE2 |
| NCT06248671 | RECRUITING | Episodic Migraine |
St. Olavs Hospital |
2024-05-01 | PHASE2 |
| NCT06785727 | NOT_YET_RECRUITING | Ischemic Stroke; Transient Ischemic Attack |
Prof. dr. Nathalie van der Velde |
2025-02-01 | PHASE4 |
| NCT06785727 | NOT_YET_RECRUITING | Ischemic Stroke; Transient Ischemic Attack |
Prof. dr. Nathalie van der Velde |
2025-02-01 | PHASE4 |
| NCT07474649 | NOT_YET_RECRUITING | Coronary Atherosclerosis; Mixed Dyslipidemia; Hypercholesterolemia |
Daiichi Sankyo |
2026-08-15 | PHASE3 |
| NCT07474649 | NOT_YET_RECRUITING | Coronary Atherosclerosis; Mixed Dyslipidemia; Hypercholesterolemia |
Daiichi Sankyo |
2026-08-15 | PHASE3 |
| NCT07568574 | ENROLLING_BY_INVITATION | Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes |
Enhanced Emirates Limited |
2026-03-12 | |
| NCT07568574 | ENROLLING_BY_INVITATION | Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes |
Enhanced Emirates Limited |
2026-03-12 | |
| NCT05796973 | RECRUITING | Prostate Cancer; Breast Cancer; Kidney Cancer; Ovarian Cancer; Metastatic Breast Cancer; Metastatic Kidney Cancer; Metastatic Renal Cell Carcinoma; Metastatic Renal Cancer; Metastatic Prostate Cancer; Metastatic Prostate Adenocarcinoma; Metastatic Ovarian Cancer; Metastatic Ovary Cancer |
Tampere University Hospital |
2023-03-31 | PHASE3 |
| NCT07045142 | RECRUITING | Schizophrenia |
Central South University |
2025-07-01 | PHASE3 |
| NCT05796973 | RECRUITING | Prostate Cancer; Breast Cancer; Kidney Cancer; Ovarian Cancer; Metastatic Breast Cancer; Metastatic Kidney Cancer; Metastatic Renal Cell Carcinoma; Metastatic Renal Cancer; Metastatic Prostate Cancer; Metastatic Prostate Adenocarcinoma; Metastatic Ovarian Cancer; Metastatic Ovary Cancer |
Tampere University Hospital |
2023-03-31 | PHASE3 |
| NCT07045142 | RECRUITING | Schizophrenia |
Central South University |
2025-07-01 | PHASE3 |
| NCT07727681 | RECRUITING | Postoperative Atrial Fibrillation; Lung Surgery |
Peking Union Medical College Hospital |
2026-08-01 | PHASE4 |
| NCT07727681 | RECRUITING | Postoperative Atrial Fibrillation; Lung Surgery |
Peking Union Medical College Hospital |
2026-08-01 | PHASE4 |
| NCT07680595 | RECRUITING | Carotid Atherosclerotic Plaque |
Ruijin Hospital |
2026-03-01 | PHASE1; PHASE2 |
| NCT07680595 | RECRUITING | Carotid Atherosclerotic Plaque |
Ruijin Hospital |
2026-03-01 | PHASE1; PHASE2 |
| NCT07530640 | RECRUITING | Kawasaki Disease; Coronary Artery Abnormalities |
Children's Hospital of Fudan University |
2026-06-08 | PHASE3 |
| NCT07530640 | RECRUITING | Kawasaki Disease; Coronary Artery Abnormalities |
Children's Hospital of Fudan University |
2026-06-08 | PHASE3 |
| NCT04765137 | RECRUITING | Mild Cognitive Impairment |
Johns Hopkins University |
2021-05-21 | PHASE2 |
| NCT04765137 | RECRUITING | Mild Cognitive Impairment |
Johns Hopkins University |
2021-05-21 | PHASE2 |
| NCT07762105 | NOT_YET_RECRUITING | Thyroid Eye Disease; Graves Ophthalmopathy; Graves Orbitopathy |
Banu Aji Dibyasakti |
2026-08-30 | PHASE1 |
| NCT07762105 | NOT_YET_RECRUITING | Thyroid Eye Disease; Graves Ophthalmopathy; Graves Orbitopathy |
Banu Aji Dibyasakti |
2026-08-30 | PHASE1 |
| NCT05641753 | RECRUITING | Type 1 Diabetes |
NYU Langone Health |
2022-12-06 | PHASE4 |
| NCT05641753 | RECRUITING | Type 1 Diabetes |
NYU Langone Health |
2022-12-06 | PHASE4 |
| NCT07634341 | NOT_YET_RECRUITING | Chronic Periodontitis |
Fayoum University |
2026-06 | PHASE4 |
| NCT07634341 | NOT_YET_RECRUITING | Chronic Periodontitis |
Fayoum University |
2026-06 | PHASE4 |
| NCT04735263 | RECRUITING | Age-related Macular Degeneration |
Massachusetts Eye and Ear Infirmary |
2021-02-04 | PHASE2 |
| NCT04735263 | RECRUITING | Age-related Macular Degeneration |
Massachusetts Eye and Ear Infirmary |
2021-02-04 | PHASE2 |
| NCT06785974 | NOT_YET_RECRUITING | Atherosclerosis; Melanoma; Immune-related Adverse Event |
Erasmus Medical Center |
2025-02 | PHASE4 |
| NCT06785974 | NOT_YET_RECRUITING | Atherosclerosis; Melanoma; Immune-related Adverse Event |
Erasmus Medical Center |
2025-02 | PHASE4 |
| NCT06369571 | ENROLLING_BY_INVITATION | Epilepsy; Dyslipidemia |
Johns Hopkins University |
2024-10-04 | PHASE1; PHASE2 |
| NCT06369571 | ENROLLING_BY_INVITATION | Epilepsy; Dyslipidemia |
Johns Hopkins University |
2024-10-04 | PHASE1; PHASE2 |
| NCT04789057 | ACTIVE_NOT_RECRUITING | Copd; COPD Exacerbation; Smoking; Gene Expression; Atorvastatin |
Medical University of Bialystok |
2022-02-11 | PHASE4 |
| NCT03127631 | ACTIVE_NOT_RECRUITING | Prostate Cancer; Cardiovascular Disease |
McMaster University |
2015-10-21 | |
| NCT04262206 | RECRUITING | Cognitive Impairment, Mild; Dementia; Cardiovascular Diseases |
Duke University |
2020-09-01 | PHASE4 |
| NCT03127631 | ACTIVE_NOT_RECRUITING | Prostate Cancer; Cardiovascular Disease |
McMaster University |
2015-10-21 | |
| NCT04262206 | RECRUITING | Cognitive Impairment, Mild; Dementia; Cardiovascular Diseases |
Duke University |
2020-09-01 | PHASE4 |
| NCT05028829 | RECRUITING | Liver Fibroses; Cirrhosis |
Raymond Chung |
2023-05-10 | PHASE2 |
| NCT04789057 | ACTIVE_NOT_RECRUITING | Copd; COPD Exacerbation; Smoking; Gene Expression; Atorvastatin |
Medical University of Bialystok |
2022-02-11 | PHASE4 |
| NCT05028829 | RECRUITING | Liver Fibroses; Cirrhosis |
Raymond Chung |
2023-05-10 | PHASE2 |
| NCT07389304 | NOT_YET_RECRUITING | Lipid Profile,Blood Pressure |
Shaheed Benazir Bhutto University Sheringal Dir Upper |
2026-03-01 | PHASE1 |
| NCT07389304 | NOT_YET_RECRUITING | Lipid Profile,Blood Pressure |
Shaheed Benazir Bhutto University Sheringal Dir Upper |
2026-03-01 | PHASE1 |
| NCT06974084 | NOT_YET_RECRUITING | Long COVID |
HealthBio, Inc. |
2026-07-15 | PHASE2; PHASE3 |
| NCT06974084 | NOT_YET_RECRUITING | Long COVID |
HealthBio, Inc. |
2026-07-15 | PHASE2; PHASE3 |
| NCT07785934 | RECRUITING | Drug Drug Interaction (DDI); Pharmacokinetics and Pharmacodynamics |
The United Bio-Technology (Hengqin) Co., Ltd. |
2026-05-27 | PHASE1 |
| NCT05589454 | NOT_YET_RECRUITING | Acute Ischemic Stroke; Cerebral Microbleeds |
Sichuan Provincial People's Hospital |
2023-01 | PHASE4 |
| NCT04679376 | ACTIVE_NOT_RECRUITING | NASH - Nonalcoholic Steatohepatitis |
Mayo Clinic |
2023-01-25 | PHASE2 |
| NCT07785934 | RECRUITING | Drug Drug Interaction (DDI); Pharmacokinetics and Pharmacodynamics |
The United Bio-Technology (Hengqin) Co., Ltd. |
2026-05-27 | PHASE1 |
| NCT05589454 | NOT_YET_RECRUITING | Acute Ischemic Stroke; Cerebral Microbleeds |
Sichuan Provincial People's Hospital |
2023-01 | PHASE4 |
| NCT04679376 | ACTIVE_NOT_RECRUITING | NASH - Nonalcoholic Steatohepatitis |
Mayo Clinic |
2023-01-25 | PHASE2 |
| NCT07088250 | RECRUITING | Cerebrovascular Disorders; Intracranial Hemorrhages; Intracranial Hemorrhage; Intracerebral Haemorrhage |
The Second Hospital of Anhui Medical University |
2023-05-06 | |
| NCT07088250 | RECRUITING | Cerebrovascular Disorders; Intracranial Hemorrhages; Intracranial Hemorrhage; Intracerebral Haemorrhage |
The Second Hospital of Anhui Medical University |
2023-05-06 | |
| NCT05910476 | ACTIVE_NOT_RECRUITING | Coronary Artery Disease; Dyslipidemias |
Yonsei University |
2023-05-03 | PHASE4 |
| NCT05910476 | ACTIVE_NOT_RECRUITING | Coronary Artery Disease; Dyslipidemias |
Yonsei University |
2023-05-03 | PHASE4 |
| NCT07608705 | RECRUITING | Hyperlipidemias |
Shandong Suncadia Medicine Co., Ltd. |
2026-06-08 | PHASE1 |
| NCT07608705 | RECRUITING | Hyperlipidemias |
Shandong Suncadia Medicine Co., Ltd. |
2026-06-08 | PHASE1 |
| NCT02726555 | UNKNOWN | Dyslipidemia; Atherosclerosis |
Wenzhou Medical University |
2015-11 | PHASE3 |
| NCT02726555 | UNKNOWN | Dyslipidemia; Atherosclerosis |
Wenzhou Medical University |
2015-11 | PHASE3 |
| NCT06750783 | RECRUITING | Prediabetic State (IGT) |
Beijing Tsinghua Chang Gung Hospital |
2024-12-31 | PHASE4 |
| NCT06750783 | RECRUITING | Prediabetic State (IGT) |
Beijing Tsinghua Chang Gung Hospital |
2024-12-31 | PHASE4 |
| NCT07265466 | RECRUITING | Drug Drug Interaction (DDI) |
Onconic Therapeutics Inc. |
2025-11-17 | PHASE1 |
| NCT06199921 | RECRUITING | Pulmonary Tuberculosis; Tuberculosis; Koch's Disease |
Obafemi Awolowo University Teaching Hospital |
2024-01-03 | PHASE2 |
| NCT07265466 | RECRUITING | Drug Drug Interaction (DDI) |
Onconic Therapeutics Inc. |
2025-11-17 | PHASE1 |
| NCT06199921 | RECRUITING | Pulmonary Tuberculosis; Tuberculosis; Koch's Disease |
Obafemi Awolowo University Teaching Hospital |
2024-01-03 | PHASE2 |
| NCT07268625 | COMPLETED | Healthy Subjects |
Daiichi Sankyo |
2025-12-09 | PHASE1 |
| NCT07268625 | COMPLETED | Healthy Subjects |
Daiichi Sankyo |
2025-12-09 | PHASE1 |
| NCT06559072 | NOT_YET_RECRUITING | Subarachnoid Hemorrhage; Subarachnoid Hemorrhage, Aneurysmal; Aneurysmal Subarachnoid Hemorrhage; Hemorrhage, Aneurysmal Subarachnoid |
The George Institute |
2024-09-01 | PHASE3 |
| NCT06765265 | RECRUITING | Acute Coronary Syndromes |
King Edward Medical University |
2025-01-05 | PHASE4 |
| NCT06765265 | RECRUITING | Acute Coronary Syndromes |
King Edward Medical University |
2025-01-05 | PHASE4 |
| NCT06559072 | NOT_YET_RECRUITING | Subarachnoid Hemorrhage; Subarachnoid Hemorrhage, Aneurysmal; Aneurysmal Subarachnoid Hemorrhage; Hemorrhage, Aneurysmal Subarachnoid |
The George Institute |
2024-09-01 | PHASE3 |
| NCT05049603 | NOT_YET_RECRUITING | Graves' Orbitopathy |
University of Pisa |
2024-01-01 | PHASE3 |
| NCT06273215 | UNKNOWN | Diabetes |
Peking University Third Hospital |
2023-03-05 | PHASE4 |
| NCT05049603 | NOT_YET_RECRUITING | Graves' Orbitopathy |
University of Pisa |
2024-01-01 | PHASE3 |
| NCT06273215 | UNKNOWN | Diabetes |
Peking University Third Hospital |
2023-03-05 | PHASE4 |
| NCT07362030 | ACTIVE_NOT_RECRUITING | Obesity |
Guangdong Raynovent Biotech Co., Ltd |
2025-04-14 | PHASE1 |
| NCT07362030 | ACTIVE_NOT_RECRUITING | Obesity |
Guangdong Raynovent Biotech Co., Ltd |
2025-04-14 | PHASE1 |
| NCT06841536 | COMPLETED | Dyslipidemias |
University of the Faroe Islands |
2025-05-01 | |
| NCT06841536 | COMPLETED | Dyslipidemias |
University of the Faroe Islands |
2025-05-01 | |
| NCT04767984 | ACTIVE_NOT_RECRUITING | Colorectal Carcinoma; Ulcerative Colitis |
Northwestern University |
2021-09-24 | PHASE2 |
| NCT04767984 | ACTIVE_NOT_RECRUITING | Colorectal Carcinoma; Ulcerative Colitis |
Northwestern University |
2021-09-24 | PHASE2 |
| NCT05912686 | UNKNOWN | Mechanical Thrombectomy; Acute Ischemic Stroke |
Zhongda Hospital |
2023-07-01 | PHASE4 |
| NCT05912686 | UNKNOWN | Mechanical Thrombectomy; Acute Ischemic Stroke |
Zhongda Hospital |
2023-07-01 | PHASE4 |
| NCT02099123 | ACTIVE_NOT_RECRUITING | Independent Living; Disability Free Survival; Elderly; Healthy |
Monash University |
2015-07 | PHASE4 |
| NCT06690164 | RECRUITING | Metabolite |
National University Hospital, Singapore |
2025-06-12 | PHASE4 |
| NCT02099123 | ACTIVE_NOT_RECRUITING | Independent Living; Disability Free Survival; Elderly; Healthy |
Monash University |
2015-07 | PHASE4 |
| NCT06690164 | RECRUITING | Metabolite |
National University Hospital, Singapore |
2025-06-12 | PHASE4 |
| NCT06948747 | COMPLETED | Healthy Participants |
AstraZeneca |
2025-05-06 | PHASE1 |
| NCT06948747 | COMPLETED | Healthy Participants |
AstraZeneca |
2025-05-06 | PHASE1 |
| NCT06360120 | RECRUITING | Ischemic Stroke |
Kafrelsheikh University |
2024-04-10 | PHASE3 |
| NCT06360120 | RECRUITING | Ischemic Stroke |
Kafrelsheikh University |
2024-04-10 | PHASE3 |
| NCT04379999 | COMPLETED | Lynch Syndrome |
Fox Chase Cancer Center |
2018-09-10 | EARLY_PHASE1 |
| NCT04379999 | COMPLETED | Lynch Syndrome |
Fox Chase Cancer Center |
2018-09-10 | EARLY_PHASE1 |
| NCT06784557 | RECRUITING | Atherosclerotic Cardiovascular Disease With Dyslipidemia |
Yonsei University |
2024-02-28 | PHASE4 |
| NCT06784557 | RECRUITING | Atherosclerotic Cardiovascular Disease With Dyslipidemia |
Yonsei University |
2024-02-28 | PHASE4 |
| NCT04904536 | ACTIVE_NOT_RECRUITING | Neurocognitive Impairment, Mild |
The George Institute |
2022-03-10 | PHASE3 |
| NCT04904536 | ACTIVE_NOT_RECRUITING | Neurocognitive Impairment, Mild |
The George Institute |
2022-03-10 | PHASE3 |
| NCT06723691 | COMPLETED | Type 2 Diabetes |
Fujian Shengdi Pharmaceutical Co., Ltd. |
2024-12-18 | PHASE1 |
| NCT06723691 | COMPLETED | Type 2 Diabetes |
Fujian Shengdi Pharmaceutical Co., Ltd. |
2024-12-18 | PHASE1 |
| NCT05567068 | COMPLETED | Inflammatory Bowel Diseases |
Tanta University |
2023-02-01 | PHASE2 |
| NCT05567068 | COMPLETED | Inflammatory Bowel Diseases |
Tanta University |
2023-02-01 | PHASE2 |
| NCT06976866 | ACTIVE_NOT_RECRUITING | In Recent Years, There Has Been a Rise in the Use of Immediate Loading Protocols; Dental Implant Stability |
Amira attia |
2023-07-13 | |
| NCT06976866 | ACTIVE_NOT_RECRUITING | In Recent Years, There Has Been a Rise in the Use of Immediate Loading Protocols; Dental Implant Stability |
Amira attia |
2023-07-13 | |
| NCT06567327 | COMPLETED | Obesity |
Pfizer |
2024-08-28 | PHASE1 |
| NCT06567327 | COMPLETED | Obesity |
Pfizer |
2024-08-28 | PHASE1 |
| NCT06601517 | NOT_YET_RECRUITING | Healthy Adult Subject; Overweight Subject |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
2024-10 | PHASE1 |
| NCT06601517 | NOT_YET_RECRUITING | Healthy Adult Subject; Overweight Subject |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
2024-10 | PHASE1 |
| NCT04601116 | RECRUITING | Breast Cancer Female; Estrogen Receptor Positive Tumor |
Aarhus University Hospital |
2021-01-04 | PHASE3 |
| NCT04601116 | RECRUITING | Breast Cancer Female; Estrogen Receptor Positive Tumor |
Aarhus University Hospital |
2021-01-04 | PHASE3 |
| NCT05165251 | UNKNOWN | Isolated Systolic Hypertension |
Shanghai Jiao Tong University School of Medicine |
2022-01-04 | PHASE4 |
| NCT05165251 | UNKNOWN | Isolated Systolic Hypertension |
Shanghai Jiao Tong University School of Medicine |
2022-01-04 | PHASE4 |
| NCT06024096 | COMPLETED | Vaccine Response |
Emory University |
2023-09-20 | PHASE4 |
| NCT06024096 | COMPLETED | Vaccine Response |
Emory University |
2023-09-20 | PHASE4 |
| NCT05561062 | COMPLETED | Inflammatory Bowel Diseases |
Tanta University |
2022-12-01 | PHASE2 |
| NCT05561062 | COMPLETED | Inflammatory Bowel Diseases |
Tanta University |
2022-12-01 | PHASE2 |
| NCT04900155 | UNKNOWN | STEMI; Covid19; NSTEMI |
Penza State University |
2020-11-20 | |
| NCT04900155 | UNKNOWN | STEMI; Covid19; NSTEMI |
Penza State University |
2020-11-20 | |
| NCT06871358 | COMPLETED | STEMI (STE-ACS); Primary PCI for STEMI |
Universitas Sebelas Maret |
2024-09-01 | |
| NCT06871358 | COMPLETED | STEMI (STE-ACS); Primary PCI for STEMI |
Universitas Sebelas Maret |
2024-09-01 | |
| NCT07668076 | COMPLETED | Breast Cancer; Doxorubicin Induced Cardiomyopathy |
Damanhour University |
2022-11-15 | PHASE2 |
| NCT07668076 | COMPLETED | Breast Cancer; Doxorubicin Induced Cardiomyopathy |
Damanhour University |
2022-11-15 | PHASE2 |
| NCT06289504 | COMPLETED | Obesity |
Novo Nordisk A/S |
2024-02-27 | PHASE1 |
| NCT06289504 | COMPLETED | Obesity |
Novo Nordisk A/S |
2024-02-27 | PHASE1 |
| NCT05930028 | COMPLETED | Essential Hypertension; Primary Hypercholesterolemia |
Boryung Pharmaceutical Co., Ltd |
2023-07-13 | PHASE3 |
| NCT05930028 | COMPLETED | Essential Hypertension; Primary Hypercholesterolemia |
Boryung Pharmaceutical Co., Ltd |
2023-07-13 | PHASE3 |
| NCT02603328 | COMPLETED | Cerebral Cavernous Malformation |
University of Chicago |
2018-07-17 | PHASE1; PHASE2 |
| NCT02603328 | COMPLETED | Cerebral Cavernous Malformation |
University of Chicago |
2018-07-17 | PHASE1; PHASE2 |
| NCT05747768 | UNKNOWN | Chronic Kidney Disease |
Peking University Third Hospital |
2022-07-15 | PHASE4 |
| NCT05845580 | COMPLETED | Drug Adherence |
Lithuanian University of Health Sciences |
2023-06-01 | |
| NCT05747768 | UNKNOWN | Chronic Kidney Disease |
Peking University Third Hospital |
2022-07-15 | PHASE4 |
| NCT07378228 | COMPLETED | Coronary Heart Disease; Stable Angina Pectoris |
Xikun Li |
2023-07-01 | |
| NCT07378228 | COMPLETED | Coronary Heart Disease; Stable Angina Pectoris |
Xikun Li |
2023-07-01 | |
| NCT05845580 | COMPLETED | Drug Adherence |
Lithuanian University of Health Sciences |
2023-06-01 | |
| NCT05327595 | COMPLETED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2022-05-09 | PHASE1 |
| NCT05327595 | COMPLETED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2022-05-09 | PHASE1 |
| NCT06293742 | COMPLETED | Type 2 Diabetes Mellitus |
Eccogene |
2024-02-08 | PHASE1 |
| NCT06293742 | COMPLETED | Type 2 Diabetes Mellitus |
Eccogene |
2024-02-08 | PHASE1 |
| NCT05238012 | COMPLETED | Metabolism Disorder, Lipid; Metabolism Disorder, Glucose |
Heart Health Research Center |
2022-08-02 | PHASE4 |
| NCT05238012 | COMPLETED | Metabolism Disorder, Lipid; Metabolism Disorder, Glucose |
Heart Health Research Center |
2022-08-02 | PHASE4 |
| NCT04181749 | UNKNOWN | Cardiovascular Risk Factor |
University of Leicester |
2020-11-18 | PHASE2 |
| NCT04181749 | UNKNOWN | Cardiovascular Risk Factor |
University of Leicester |
2020-11-18 | PHASE2 |
| NCT05790499 | UNKNOWN | Cholesterol Variability; Trained Immunity |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2023-03-20 | |
| NCT05790499 | UNKNOWN | Cholesterol Variability; Trained Immunity |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2023-03-20 | |
| NCT06699355 | COMPLETED | Healthy |
Merck Sharp & Dohme LLC |
2023-11-08 | PHASE1 |
| NCT06699355 | COMPLETED | Healthy |
Merck Sharp & Dohme LLC |
2023-11-08 | PHASE1 |
| NCT02022293 | SUSPENDED | Nasopharyngeal Carcinoma; Radiation Therapy Complication |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2017-01 | PHASE2 |
| NCT02022293 | SUSPENDED | Nasopharyngeal Carcinoma; Radiation Therapy Complication |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2017-01 | PHASE2 |
| NCT07578857 | COMPLETED | Hyperlipidemias |
Riphah International University |
2023-05-24 | |
| NCT07578857 | COMPLETED | Hyperlipidemias |
Riphah International University |
2023-05-24 | |
| NCT05815680 | COMPLETED | Overweight Subjects; Obese Subjects |
Innovent Biologics (Suzhou) Co. Ltd. |
2023-04-06 | PHASE1 |
| NCT05815680 | COMPLETED | Overweight Subjects; Obese Subjects |
Innovent Biologics (Suzhou) Co. Ltd. |
2023-04-06 | PHASE1 |
| NCT06053983 | COMPLETED | Mi Q Wave |
Rawalpindi Medical College |
2023-01-01 | PHASE4 |
| NCT06053983 | COMPLETED | Mi Q Wave |
Rawalpindi Medical College |
2023-01-01 | PHASE4 |
| NCT04685642 | UNKNOWN | Mood Disorder |
Taipei Veterans General Hospital, Taiwan |
2020-08-24 | PHASE4 |
| NCT04685642 | UNKNOWN | Mood Disorder |
Taipei Veterans General Hospital, Taiwan |
2020-08-24 | PHASE4 |
| NCT05839236 | UNKNOWN | COVID-19 Stress Syndrome; COVID-19 Vaccine Adverse Reaction; COVID-19-Associated Thromboembolism; COVID-19 Post-Intensive Care Syndrome; COVID-19-Associated Stroke; COVID-19 Respiratory Infection |
Yang I. Pachankis |
2023-05-01 | PHASE1 |
| NCT05839236 | UNKNOWN | COVID-19 Stress Syndrome; COVID-19 Vaccine Adverse Reaction; COVID-19-Associated Thromboembolism; COVID-19 Post-Intensive Care Syndrome; COVID-19-Associated Stroke; COVID-19 Respiratory Infection |
Yang I. Pachankis |
2023-05-01 | PHASE1 |
| NCT02790528 | WITHDRAWN | Angina Pectoris, Variant; Statins, HMG-CoA |
Seung-Jung Park |
2017-07 | PHASE4 |
| NCT05792293 | UNKNOWN | Doxorubicin Induced Cardiomyopathy |
Ain Shams University |
2021-06-01 | PHASE2; PHASE3 |
| NCT02790528 | WITHDRAWN | Angina Pectoris, Variant; Statins, HMG-CoA |
Seung-Jung Park |
2017-07 | PHASE4 |
| NCT05792293 | UNKNOWN | Doxorubicin Induced Cardiomyopathy |
Ain Shams University |
2021-06-01 | PHASE2; PHASE3 |
| NCT05681273 | COMPLETED | T2DM |
Chipscreen Biosciences, Ltd. |
2023-02-17 | PHASE1 |
| NCT05681273 | COMPLETED | T2DM |
Chipscreen Biosciences, Ltd. |
2023-02-17 | PHASE1 |
| NCT04661709 | UNKNOWN | Coronary Heart Disease; Unstable Angina; Chinese Herbal Medicine |
Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
2021-03-01 | PHASE4 |
| NCT04661709 | UNKNOWN | Coronary Heart Disease; Unstable Angina; Chinese Herbal Medicine |
Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
2021-03-01 | PHASE4 |
| NCT05679102 | COMPLETED | Atorvastatin Antihypertensive Effect |
Himayat Ullah |
2022-12-20 | |
| NCT05679102 | COMPLETED | Atorvastatin Antihypertensive Effect |
Himayat Ullah |
2022-12-20 | |
| NCT07128212 | COMPLETED | Ischemic White Matter Lesions (WMIL); Cerebral Small Vessel Disease; Vascular Cell Adhesion Molecule-1; VCAM-1 |
Suzhou Municipal Hospital of Anhui Province |
2021-01-01 | |
| NCT04945122 | UNKNOWN | Acute Myocardial Infarction; Glucose Metabolism Disorders |
Chinese Academy of Medical Sciences, Fuwai Hospital |
2015-10-01 | PHASE4 |
| NCT07128212 | COMPLETED | Ischemic White Matter Lesions (WMIL); Cerebral Small Vessel Disease; Vascular Cell Adhesion Molecule-1; VCAM-1 |
Suzhou Municipal Hospital of Anhui Province |
2021-01-01 | |
| NCT04945122 | UNKNOWN | Acute Myocardial Infarction; Glucose Metabolism Disorders |
Chinese Academy of Medical Sciences, Fuwai Hospital |
2015-10-01 | PHASE4 |
| NCT05642845 | COMPLETED | Bioequivalence |
Pharmtechnology LLC |
2022-11-19 | PHASE1 |
| NCT05642845 | COMPLETED | Bioequivalence |
Pharmtechnology LLC |
2022-11-19 | PHASE1 |
| NCT04744571 | UNKNOWN | Coronary Artery Disease; Coronary Occlusion; Percutaneous Coronary Intervention; Chronic Total Occlusion of Coronary Artery; Drug-Eluting Stents |
Beijing Anzhen Hospital |
2021-02 | |
| NCT04744571 | UNKNOWN | Coronary Artery Disease; Coronary Occlusion; Percutaneous Coronary Intervention; Chronic Total Occlusion of Coronary Artery; Drug-Eluting Stents |
Beijing Anzhen Hospital |
2021-02 | |
| NCT03830164 | COMPLETED | Male Erectile Disorder; Prostate Adenocarcinoma; Erectile Dysfunction, CTCAE; Impotence |
M.D. Anderson Cancer Center |
2019-11-20 | PHASE2 |
| NCT03830164 | COMPLETED | Male Erectile Disorder; Prostate Adenocarcinoma; Erectile Dysfunction, CTCAE; Impotence |
M.D. Anderson Cancer Center |
2019-11-20 | PHASE2 |
| NCT03560882 | ACTIVE_NOT_RECRUITING | Malignant Disease; Solid Tumor; Acute Myeloid Leukemia; Myelodysplastic Syndromes; Cancer; Relapsed Hematologic Malignancy |
Joaquina Baranda |
2018-07-19 | PHASE1 |
| NCT03560882 | ACTIVE_NOT_RECRUITING | Malignant Disease; Solid Tumor; Acute Myeloid Leukemia; Myelodysplastic Syndromes; Cancer; Relapsed Hematologic Malignancy |
Joaquina Baranda |
2018-07-19 | PHASE1 |
| NCT04974814 | UNKNOWN | ST Elevation Myocardial Infarction |
Beni-Suef University |
2021-05-26 | |
| NCT04974814 | UNKNOWN | ST Elevation Myocardial Infarction |
Beni-Suef University |
2021-05-26 | |
| NCT03956368 | UNKNOWN | Chronic Subdural Hematoma |
Chinese University of Hong Kong |
2020-01-09 | PHASE3 |
| NCT02943590 | COMPLETED | Heart Failure |
Massachusetts General Hospital |
2017-01-13 | PHASE2 |
| NCT03956368 | UNKNOWN | Chronic Subdural Hematoma |
Chinese University of Hong Kong |
2020-01-09 | PHASE3 |
| NCT02943590 | COMPLETED | Heart Failure |
Massachusetts General Hospital |
2017-01-13 | PHASE2 |
| NCT04072601 | TERMINATED | Liver Cirrhoses |
Copenhagen University Hospital, Hvidovre |
2019-11-08 | PHASE4 |
| NCT04072601 | TERMINATED | Liver Cirrhoses |
Copenhagen University Hospital, Hvidovre |
2019-11-08 | PHASE4 |
| NCT05093205 | COMPLETED | Healthy Adults |
Pfizer |
2021-10-25 | PHASE1 |
| NCT05093205 | COMPLETED | Healthy Adults |
Pfizer |
2021-10-25 | PHASE1 |
| NCT05072054 | UNKNOWN | Heart Failure With Reduced Ejection Fraction |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2019-10-16 | PHASE4 |
| NCT03037372 | UNKNOWN | HIV Infection |
Makerere University |
2017-06-01 | PHASE3 |
| NCT05072054 | UNKNOWN | Heart Failure With Reduced Ejection Fraction |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2019-10-16 | PHASE4 |
| NCT03037372 | UNKNOWN | HIV Infection |
Makerere University |
2017-06-01 | PHASE3 |
| NCT05331053 | TERMINATED | Endometriosis |
Penn State University |
2018-05-01 | PHASE4 |
| NCT05331053 | TERMINATED | Endometriosis |
Penn State University |
2018-05-01 | PHASE4 |
| NCT05730634 | COMPLETED | Diabetes Mellitus, Type 2; Vascular Inflammation |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2019-06-01 | |
| NCT05730634 | COMPLETED | Diabetes Mellitus, Type 2; Vascular Inflammation |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2019-06-01 | |
| NCT03943459 | UNKNOWN | Coronary Artery Disease Progression |
InCor Heart Institute |
2019-08-02 | PHASE3 |
| NCT03943459 | UNKNOWN | Coronary Artery Disease Progression |
InCor Heart Institute |
2019-08-02 | PHASE3 |
| NCT04718155 | COMPLETED | Traumatic Brain Injury |
Assiut University |
2021-03-01 | |
| NCT04718155 | COMPLETED | Traumatic Brain Injury |
Assiut University |
2021-03-01 | |
| NCT05583643 | COMPLETED | Periodontitis |
Misr University for Science and Technology |
2021-12-07 | PHASE1 |
| NCT05583643 | COMPLETED | Periodontitis |
Misr University for Science and Technology |
2021-12-07 | PHASE1 |
| NCT04721795 | COMPLETED | Tuberculosis, Pulmonary; Tuberculosis |
Obafemi Awolowo University Teaching Hospital |
2021-01-19 | PHASE2; PHASE3 |
| NCT04721795 | COMPLETED | Tuberculosis, Pulmonary; Tuberculosis |
Obafemi Awolowo University Teaching Hospital |
2021-01-19 | PHASE2; PHASE3 |
| NCT02740699 | TERMINATED | Cardiovascular Disease |
National Heart, Lung, and Blood Institute (NHLBI) |
2016-04-11 | PHASE4 |
| NCT02740699 | TERMINATED | Cardiovascular Disease |
National Heart, Lung, and Blood Institute (NHLBI) |
2016-04-11 | PHASE4 |
| NCT03418974 | UNKNOWN | Dyslipidemias |
Fudan University |
2017-11-01 | PHASE4 |
| NCT03418974 | UNKNOWN | Dyslipidemias |
Fudan University |
2017-11-01 | PHASE4 |
| NCT04333407 | TERMINATED | COVID-19 |
Imperial College London |
2020-04-03 | |
| NCT04333407 | TERMINATED | COVID-19 |
Imperial College London |
2020-04-03 | |
| NCT04466241 | COMPLETED | COVID-19; COVID-19 Drug Treatment; Severe Acute Respiratory Syndrome Coronavirus 2 |
ANRS, Emerging Infectious Diseases |
2020-11-27 | PHASE2; PHASE3 |
| NCT04466241 | COMPLETED | COVID-19; COVID-19 Drug Treatment; Severe Acute Respiratory Syndrome Coronavirus 2 |
ANRS, Emerging Infectious Diseases |
2020-11-27 | PHASE2; PHASE3 |
| NCT04251364 | COMPLETED | Hypoxia, Altitude |
Centre d'Expertise sur l'Altitude EXALT |
2020-02-15 | |
| NCT04251364 | COMPLETED | Hypoxia, Altitude |
Centre d'Expertise sur l'Altitude EXALT |
2020-02-15 | |
| NCT04388501 | COMPLETED | Healthy |
Janssen Pharmaceutica N.V., Belgium |
2021-06-07 | PHASE1 |
| NCT04388501 | COMPLETED | Healthy |
Janssen Pharmaceutica N.V., Belgium |
2021-06-07 | PHASE1 |
| NCT03951207 | COMPLETED | Dyslipidemias; Hypertension |
Yuhan Corporation |
2019-05-30 | PHASE4 |
| NCT03951207 | COMPLETED | Dyslipidemias; Hypertension |
Yuhan Corporation |
2019-05-30 | PHASE4 |
| NCT01665677 | COMPLETED | Graft vs Host Disease |
Mehdi Hamadani |
2014-01-20 | PHASE2 |
| NCT01665677 | COMPLETED | Graft vs Host Disease |
Mehdi Hamadani |
2014-01-20 | PHASE2 |
| NCT04270370 | COMPLETED | Healthy |
Eli Lilly and Company |
2020-03-16 | PHASE1 |
| NCT04270370 | COMPLETED | Healthy |
Eli Lilly and Company |
2020-03-16 | PHASE1 |
| NCT03358017 | COMPLETED | Triple Negative Breast Cancer |
Mario Negri Institute for Pharmacological Research |
2018-03-05 | PHASE2 |
| NCT03358017 | COMPLETED | Triple Negative Breast Cancer |
Mario Negri Institute for Pharmacological Research |
2018-03-05 | PHASE2 |
| NCT00911339 | TERMINATED | Stable Coronary Artery Disease |
Fondazione IRCCS Policlinico San Matteo di Pavia |
2009-01 | PHASE3 |
| NCT00911339 | TERMINATED | Stable Coronary Artery Disease |
Fondazione IRCCS Policlinico San Matteo di Pavia |
2009-01 | PHASE3 |
| NCT04472637 | COMPLETED | Arterial Stiffness |
Alexandria University |
2020-11-01 | PHASE2 |
| NCT04472637 | COMPLETED | Arterial Stiffness |
Alexandria University |
2020-11-01 | PHASE2 |
| NCT03110848 | COMPLETED | Thyroid Associated Ophthalmopathy; Hypercholesterolemia |
University of Pisa |
2020-06-01 | PHASE2 |
| NCT03110848 | COMPLETED | Thyroid Associated Ophthalmopathy; Hypercholesterolemia |
University of Pisa |
2020-06-01 | PHASE2 |
| NCT04486508 | COMPLETED | Covid19 |
Rajaie Cardiovascular Medical and Research Center |
2020-07-30 | PHASE3 |
| NCT04486508 | COMPLETED | Covid19 |
Rajaie Cardiovascular Medical and Research Center |
2020-07-30 | PHASE3 |
| NCT03768427 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2019-05-27 | PHASE3 |
| NCT03768427 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2019-05-27 | PHASE3 |
| NCT03510884 | COMPLETED | Hypercholesterolaemia |
Sanofi |
2018-05-31 | PHASE3 |
| NCT03510884 | COMPLETED | Hypercholesterolaemia |
Sanofi |
2018-05-31 | PHASE3 |
| NCT04608344 | COMPLETED | Rheumatoid Arthritis |
Gilead Sciences |
2020-11-04 | PHASE1 |
| NCT04608344 | COMPLETED | Rheumatoid Arthritis |
Gilead Sciences |
2020-11-04 | PHASE1 |
| NCT06094244 | COMPLETED | Intracerebral Hemorrhage |
Pomeranian Medical University Szczecin |
2017-03-17 | |
| NCT06094244 | COMPLETED | Intracerebral Hemorrhage |
Pomeranian Medical University Szczecin |
2017-03-17 | |
| NCT02863185 | COMPLETED | Chronic Kidney Disease |
Dong-A University |
2016-05-01 | PHASE4 |
| NCT02863185 | COMPLETED | Chronic Kidney Disease |
Dong-A University |
2016-05-01 | PHASE4 |
| NCT03275376 | TERMINATED | Overall Survival; Tumor Responses |
Taichung Veterans General Hospital |
2017-12-21 | PHASE2 |
| NCT03275376 | TERMINATED | Overall Survival; Tumor Responses |
Taichung Veterans General Hospital |
2017-12-21 | PHASE2 |
| NCT04453735 | COMPLETED | Statin Adverse Reaction |
Vestre Viken Hospital Trust |
2020-08-19 | PHASE4 |
| NCT04453735 | COMPLETED | Statin Adverse Reaction |
Vestre Viken Hospital Trust |
2020-08-19 | PHASE4 |
| NCT03750760 | WITHDRAWN | Myocardial Infarction; Dyslipidemias |
Imperial College London |
2020-01 | PHASE4 |
| NCT03750760 | WITHDRAWN | Myocardial Infarction; Dyslipidemias |
Imperial College London |
2020-01 | PHASE4 |
| NCT03929744 | COMPLETED | Healthy |
Eli Lilly and Company |
2019-06-12 | PHASE1 |
| NCT03929744 | COMPLETED | Healthy |
Eli Lilly and Company |
2019-06-12 | PHASE1 |
| NCT04306627 | UNKNOWN | Essential Hypertension; Hypercholesterolemia |
Yerevan State Medical University |
2020-04-15 | PHASE4 |
| NCT04306627 | UNKNOWN | Essential Hypertension; Hypercholesterolemia |
Yerevan State Medical University |
2020-04-15 | PHASE4 |
| NCT04151355 | UNKNOWN | Colorectal Cancer |
Ain Shams University |
2019-10-01 | |
| NCT04151355 | UNKNOWN | Colorectal Cancer |
Ain Shams University |
2019-10-01 | |
| NCT04215237 | UNKNOWN | Atherosclerotic Cardiovascular Disease |
First Affiliated Hospital Xi'an Jiaotong University |
2017-11-13 | |
| NCT04215237 | UNKNOWN | Atherosclerotic Cardiovascular Disease |
First Affiliated Hospital Xi'an Jiaotong University |
2017-11-13 | |
| NCT04325009 | UNKNOWN | Healthy |
Dong-A ST Co., Ltd. |
2020-03-30 | PHASE1 |
| NCT04325009 | UNKNOWN | Healthy |
Dong-A ST Co., Ltd. |
2020-03-30 | PHASE1 |
| NCT03066466 | WITHDRAWN | Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Myelodysplastic Syndrome |
Loyola University |
2019-12-10 | PHASE3 |
| NCT03066466 | WITHDRAWN | Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Myelodysplastic Syndrome |
Loyola University |
2019-12-10 | PHASE3 |
| NCT04047940 | COMPLETED | Healthy |
Eli Lilly and Company |
2019-11-29 | PHASE1 |
| NCT04047940 | COMPLETED | Healthy |
Eli Lilly and Company |
2019-11-29 | PHASE1 |
| NCT03611010 | COMPLETED | Hypercholesterolemia; Dyslipidemias |
Cumberland Pharmaceuticals |
2018-08-07 | PHASE2 |
| NCT03510715 | COMPLETED | Hypercholesterolemia |
Sanofi |
2018-08-31 | PHASE3 |
| NCT03510715 | COMPLETED | Hypercholesterolemia |
Sanofi |
2018-08-31 | PHASE3 |
| NCT03611010 | COMPLETED | Hypercholesterolemia; Dyslipidemias |
Cumberland Pharmaceuticals |
2018-08-07 | PHASE2 |
| NCT03966859 | COMPLETED | Healthy |
University of Oxford |
2019-06-19 | |
| NCT03966859 | COMPLETED | Healthy |
University of Oxford |
2019-06-19 | |
| NCT03122639 | COMPLETED | Obstructive Sleep Apnea of Adult |
Columbia University |
2017-09-01 | EARLY_PHASE1 |
| NCT03122639 | COMPLETED | Obstructive Sleep Apnea of Adult |
Columbia University |
2017-09-01 | EARLY_PHASE1 |
| NCT03874156 | COMPLETED | Statin Adverse Reaction |
Vestre Viken Hospital Trust |
2019-03-05 | PHASE4 |
| NCT03874156 | COMPLETED | Statin Adverse Reaction |
Vestre Viken Hospital Trust |
2019-03-05 | PHASE4 |
| NCT03004001 | TERMINATED | Nephrotic Syndrome |
Gloria Vega |
2017-01 | PHASE2 |
| NCT02590653 | COMPLETED | Myocardial Infarction |
Penza State University |
2014-10 | PHASE4 |
| NCT03004001 | TERMINATED | Nephrotic Syndrome |
Gloria Vega |
2017-01 | PHASE2 |
| NCT02590653 | COMPLETED | Myocardial Infarction |
Penza State University |
2014-10 | PHASE4 |
| NCT02940366 | UNKNOWN | Metabolic Syndrome |
Seoul National University Hospital |
2016-12-01 | PHASE4 |
| NCT02940366 | UNKNOWN | Metabolic Syndrome |
Seoul National University Hospital |
2016-12-01 | PHASE4 |
| NCT02081638 | COMPLETED | Human Immunodeficiency Virus |
National Institute of Allergy and Infectious Diseases (NIAID) |
2014-04-18 | PHASE2 |
| NCT02081638 | COMPLETED | Human Immunodeficiency Virus |
National Institute of Allergy and Infectious Diseases (NIAID) |
2014-04-18 | PHASE2 |
| NCT01617772 | UNKNOWN | Non-alcoholic Steatohepatitis |
Tehran University of Medical Sciences |
2016-01-01 | PHASE2 |
| NCT01617772 | UNKNOWN | Non-alcoholic Steatohepatitis |
Tehran University of Medical Sciences |
2016-01-01 | PHASE2 |
| NCT03355027 | UNKNOWN | Atherosclerosis; Cardiovascular Diseases |
Cambridge University Hospitals NHS Foundation Trust |
2017-11-30 | |
| NCT03355027 | UNKNOWN | Atherosclerosis; Cardiovascular Diseases |
Cambridge University Hospitals NHS Foundation Trust |
2017-11-30 | |
| NCT03532620 | UNKNOWN | Prediabetic State; Hypertension; Dyslipidemias |
Jun Tao |
2018-08-09 | PHASE4 |
| NCT02245087 | TERMINATED | Coronary Artery Disease |
University Health Network, Toronto |
2014-08 | PHASE2 |
| NCT03532620 | UNKNOWN | Prediabetic State; Hypertension; Dyslipidemias |
Jun Tao |
2018-08-09 | PHASE4 |
| NCT02245087 | TERMINATED | Coronary Artery Disease |
University Health Network, Toronto |
2014-08 | PHASE2 |
| NCT03604471 | COMPLETED | Hypercholesterolemia |
Université Catholique de Louvain |
2017-08-08 | PHASE4 |
| NCT03604471 | COMPLETED | Hypercholesterolemia |
Université Catholique de Louvain |
2017-08-08 | PHASE4 |
| NCT02781064 | COMPLETED | Cardiovascular Disease |
London School of Hygiene and Tropical Medicine |
2016-09-01 | PHASE4 |
| NCT02781064 | COMPLETED | Cardiovascular Disease |
London School of Hygiene and Tropical Medicine |
2016-09-01 | PHASE4 |
| NCT05306990 | COMPLETED | Hydroxymethylglutaryl-CoA Reductase Inhibitors; Diabetes Mellitus |
Helwan University |
2017-04-20 | |
| NCT05306990 | COMPLETED | Hydroxymethylglutaryl-CoA Reductase Inhibitors; Diabetes Mellitus |
Helwan University |
2017-04-20 | |
| NCT03660293 | COMPLETED | Diabetes Mellitus, Type 1 |
Tanta University |
2017-04-01 | |
| NCT03660293 | COMPLETED | Diabetes Mellitus, Type 1 |
Tanta University |
2017-04-01 | |
| NCT03054467 | UNKNOWN | Quality of Life |
Kosin University Gospel Hospital |
2018-12-01 | PHASE4 |
| NCT03054467 | UNKNOWN | Quality of Life |
Kosin University Gospel Hospital |
2018-12-01 | PHASE4 |
| NCT02476006 | COMPLETED | Hypercholesterolemia |
Sanofi |
2015-06-23 | PHASE3 |
| NCT02476006 | COMPLETED | Hypercholesterolemia |
Sanofi |
2015-06-23 | PHASE3 |
| NCT04262765 | COMPLETED | Healthy Volunteers |
Midas Pharma GmbH |
2019-02-23 | PHASE1 |
| NCT04245046 | COMPLETED | Healthy Volunteers |
Midas Pharma GmbH |
2019-01-18 | PHASE1 |
| NCT04245046 | COMPLETED | Healthy Volunteers |
Midas Pharma GmbH |
2019-01-18 | PHASE1 |
| NCT03760848 | COMPLETED | Healthy |
Galmed Pharmaceuticals Ltd |
2018-11-12 | PHASE1 |
| NCT03760848 | COMPLETED | Healthy |
Galmed Pharmaceuticals Ltd |
2018-11-12 | PHASE1 |
| NCT01674686 | UNKNOWN | Variant Angina |
Samsung Medical Center |
2012-08-01 | PHASE4 |
| NCT03047772 | UNKNOWN | Myocardial Infarction; Stem Cell Transplantation; Angioplasty, Transluminal, Percutaneous Coronary |
Yuejin Yang |
2018-03-06 | PHASE2 |
| NCT01674686 | UNKNOWN | Variant Angina |
Samsung Medical Center |
2012-08-01 | PHASE4 |
| NCT03247400 | COMPLETED | Non-segmental Vitiligo |
Nicolaus Copernicus University |
2016-12-01 | PHASE1; PHASE2 |
| NCT03047772 | UNKNOWN | Myocardial Infarction; Stem Cell Transplantation; Angioplasty, Transluminal, Percutaneous Coronary |
Yuejin Yang |
2018-03-06 | PHASE2 |
| NCT03247400 | COMPLETED | Non-segmental Vitiligo |
Nicolaus Copernicus University |
2016-12-01 | PHASE1; PHASE2 |
| NCT03464682 | UNKNOWN | Primary Hypercholesterolemia |
Zhejiang Hisun Pharmaceutical Co. Ltd. |
2015-02-28 | PHASE3 |
| NCT03464682 | UNKNOWN | Primary Hypercholesterolemia |
Zhejiang Hisun Pharmaceutical Co. Ltd. |
2015-02-28 | PHASE3 |
| NCT02370784 | COMPLETED | Scleroderma |
Robyn T. Domsic, MD, MPH |
2015-02 | PHASE2 |
| NCT02370784 | COMPLETED | Scleroderma |
Robyn T. Domsic, MD, MPH |
2015-02 | PHASE2 |
| NCT00715273 | COMPLETED | Coronary Artery Disease; Carotid Artery Diseases; Atherosclerosis |
University of Washington |
2001-05-01 | PHASE4 |
| NCT00715273 | COMPLETED | Coronary Artery Disease; Carotid Artery Diseases; Atherosclerosis |
University of Washington |
2001-05-01 | PHASE4 |
| NCT03072082 | UNKNOWN | Coronary Artery Disease(CAD) |
Jun Li |
2017-06 | PHASE4 |
| NCT03072082 | UNKNOWN | Coronary Artery Disease(CAD) |
Jun Li |
2017-06 | PHASE4 |
| NCT03801733 | COMPLETED | Drug Interaction Potentiation |
Akebia Therapeutics |
2018-06-17 | PHASE1 |
| NCT03801733 | COMPLETED | Drug Interaction Potentiation |
Akebia Therapeutics |
2018-06-17 | PHASE1 |
| NCT01527045 | COMPLETED | Aggressive Non-Hodgkin Lymphoma; Blasts Under 5 Percent of Bone Marrow Nucleated Cells; Chronic Lymphocytic Leukemia; Loss of Chromosome 17p; Myelodysplastic/Myeloproliferative Neoplasm; Non-Hodgkin Lymphoma; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Aggressive Adult Non-Hodgkin Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Hodgkin Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia |
Fred Hutchinson Cancer Center |
2012-09-25 | PHASE2 |
| NCT01527045 | COMPLETED | Aggressive Non-Hodgkin Lymphoma; Blasts Under 5 Percent of Bone Marrow Nucleated Cells; Chronic Lymphocytic Leukemia; Loss of Chromosome 17p; Myelodysplastic/Myeloproliferative Neoplasm; Non-Hodgkin Lymphoma; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Aggressive Adult Non-Hodgkin Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Hodgkin Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia |
Fred Hutchinson Cancer Center |
2012-09-25 | PHASE2 |
| NCT03311841 | COMPLETED | Renal Insufficiency |
Merck Sharp & Dohme LLC |
2018-03-01 | PHASE1 |
| NCT03311841 | COMPLETED | Renal Insufficiency |
Merck Sharp & Dohme LLC |
2018-03-01 | PHASE1 |
| NCT02984982 | COMPLETED | Hypercholesterolemia; Acute Coronary Syndrome |
Sanofi |
2016-11-15 | PHASE4 |
| NCT02984982 | COMPLETED | Hypercholesterolemia; Acute Coronary Syndrome |
Sanofi |
2016-11-15 | PHASE4 |
| NCT02056340 | COMPLETED | Influenza |
Beth Israel Deaconess Medical Center |
2013-10 | PHASE2 |
| NCT02056340 | COMPLETED | Influenza |
Beth Israel Deaconess Medical Center |
2013-10 | PHASE2 |
| NCT02278471 | COMPLETED | Hypertension; Hyperlipidemia |
Vanderbilt University |
2015-12 | PHASE2 |
| NCT02278471 | COMPLETED | Hypertension; Hyperlipidemia |
Vanderbilt University |
2015-12 | PHASE2 |
| NCT02577042 | COMPLETED | Aging-related Inflammation in HIV-infected Patients |
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia |
2015-10-15 | PHASE4 |
| NCT02577042 | COMPLETED | Aging-related Inflammation in HIV-infected Patients |
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia |
2015-10-15 | PHASE4 |
| NCT02674204 | TERMINATED | Breast Cancer; Heart Disease; Cardiotoxicity; Myocardial Dysfunction |
Cedars-Sinai Medical Center |
2016-05-05 | PHASE2 |
| NCT02674204 | TERMINATED | Breast Cancer; Heart Disease; Cardiotoxicity; Myocardial Dysfunction |
Cedars-Sinai Medical Center |
2016-05-05 | PHASE2 |
| NCT01980823 | COMPLETED | Breast Cancer; Breast Tumors; Cancer of Breast |
Columbia University |
2013-10 | EARLY_PHASE1 |
| NCT01980823 | COMPLETED | Breast Cancer; Breast Tumors; Cancer of Breast |
Columbia University |
2013-10 | EARLY_PHASE1 |
| NCT02842359 | COMPLETED | Type 2 Diabetes Mellitus |
Sanofi |
2016-08-23 | PHASE4 |
| NCT02842359 | COMPLETED | Type 2 Diabetes Mellitus |
Sanofi |
2016-08-23 | PHASE4 |
| NCT02977065 | COMPLETED | Dyslipidemias |
Chong Kun Dang Pharmaceutical |
2017-03-23 | PHASE2 |
| NCT02977065 | COMPLETED | Dyslipidemias |
Chong Kun Dang Pharmaceutical |
2017-03-23 | PHASE2 |
| NCT02364258 | COMPLETED | Dyslipidemia |
Children's Mercy Hospital Kansas City |
2014-07 | PHASE1 |
| NCT02364258 | COMPLETED | Dyslipidemia |
Children's Mercy Hospital Kansas City |
2014-07 | PHASE1 |
| NCT02662569 | COMPLETED | Diabetes, Hyperlipidemia, Mixed Dyslipidemia |
Amgen |
2016-04-14 | PHASE3 |
| NCT02662569 | COMPLETED | Diabetes, Hyperlipidemia, Mixed Dyslipidemia |
Amgen |
2016-04-14 | PHASE3 |
| NCT02588235 | UNKNOWN | Coronary Artery Disease |
Xijing Hospital |
2015-10 | PHASE4 |
| NCT02588235 | UNKNOWN | Coronary Artery Disease |
Xijing Hospital |
2015-10 | PHASE4 |
| NCT02452502 | COMPLETED | Stroke |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2015-09-02 | |
| NCT02452502 | COMPLETED | Stroke |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2015-09-02 | |
| NCT01263938 | COMPLETED | HIV Dementia |
University of Pennsylvania |
2011-09 | PHASE4 |
| NCT02791958 | UNKNOWN | Hypertension |
Ferrer Internacional S.A. |
2016-03 | PHASE2 |
| NCT02791958 | UNKNOWN | Hypertension |
Ferrer Internacional S.A. |
2016-03 | PHASE2 |
| NCT01263938 | COMPLETED | HIV Dementia |
University of Pennsylvania |
2011-09 | PHASE4 |
| NCT02957162 | COMPLETED | Acute Coronary Syndrome |
University Hospitals of North Midlands NHS Trust |
2016-03 | PHASE4 |
| NCT02957162 | COMPLETED | Acute Coronary Syndrome |
University Hospitals of North Midlands NHS Trust |
2016-03 | PHASE4 |
| NCT03461081 | COMPLETED | Hypertension With Hyperlipidemia |
Jeil Pharmaceutical Co., Ltd. |
2017-05-07 | PHASE1 |
| NCT03461081 | COMPLETED | Hypertension With Hyperlipidemia |
Jeil Pharmaceutical Co., Ltd. |
2017-05-07 | PHASE1 |
| NCT03031119 | COMPLETED | Healthy Volunteers |
Pfizer |
2017-01 | PHASE1 |
| NCT03031119 | COMPLETED | Healthy Volunteers |
Pfizer |
2017-01 | PHASE1 |
| NCT02029534 | UNKNOWN | Cardiothoracic Surgery; Post-operative Atrial Fibrillation |
Creighton University |
2013-08 | PHASE4 |
| NCT02979704 | UNKNOWN | Hyperlipidemia |
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
2016-09 | PHASE2; PHASE3 |
| NCT02979704 | UNKNOWN | Hyperlipidemia |
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
2016-09 | PHASE2; PHASE3 |
| NCT02029534 | UNKNOWN | Cardiothoracic Surgery; Post-operative Atrial Fibrillation |
Creighton University |
2013-08 | PHASE4 |
| NCT03346187 | COMPLETED | Dyslipidemias |
Chong Kun Dang Pharmaceutical |
2017-05-19 | PHASE1 |
| NCT03482180 | COMPLETED | Dyslipidemias |
Kuhnil Pharmaceutical Co., Ltd. |
2016-05-04 | PHASE3 |
| NCT03482180 | COMPLETED | Dyslipidemias |
Kuhnil Pharmaceutical Co., Ltd. |
2016-05-04 | PHASE3 |
| NCT03867994 | COMPLETED | Contrast-induced Nephropathy |
rabab ahmed mohamed |
2016-02-01 | PHASE2 |
| NCT03867994 | COMPLETED | Contrast-induced Nephropathy |
rabab ahmed mohamed |
2016-02-01 | PHASE2 |
| NCT01821404 | COMPLETED | Prostatic Neoplasms |
Tampere University Hospital |
2012-08 | PHASE2 |
| NCT01821404 | COMPLETED | Prostatic Neoplasms |
Tampere University Hospital |
2012-08 | PHASE2 |
| NCT02764736 | WITHDRAWN | Complication of Renal Dialysis |
Albert Einstein Healthcare Network |
2016-03-04 | |
| NCT02764736 | WITHDRAWN | Complication of Renal Dialysis |
Albert Einstein Healthcare Network |
2016-03-04 | |
| NCT02633956 | COMPLETED | Nonalcoholic Steatohepatitis |
Intercept Pharmaceuticals |
2015-12-04 | PHASE2 |
| NCT02633956 | COMPLETED | Nonalcoholic Steatohepatitis |
Intercept Pharmaceuticals |
2015-12-04 | PHASE2 |
| NCT03231137 | COMPLETED | Alveolar Socket Preservations |
Ain Shams University |
2012-06-16 | PHASE4 |
| NCT03231137 | COMPLETED | Alveolar Socket Preservations |
Ain Shams University |
2012-06-16 | PHASE4 |
| NCT02994745 | COMPLETED | Hypertension, Hyperlipidemia |
Boryung Pharmaceutical Co., Ltd |
2016-12-23 | PHASE1 |
| NCT02994745 | COMPLETED | Hypertension, Hyperlipidemia |
Boryung Pharmaceutical Co., Ltd |
2016-12-23 | PHASE1 |
| NCT02910778 | COMPLETED | Ischemia |
Medical University of Vienna |
2016-10 | PHASE4 |
| NCT02910778 | COMPLETED | Ischemia |
Medical University of Vienna |
2016-10 | PHASE4 |
| NCT01528709 | COMPLETED | Saphenous Vein Graft Disease |
Boca Raton Regional Hospital |
2012-03 | PHASE3 |
| NCT01528709 | COMPLETED | Saphenous Vein Graft Disease |
Boca Raton Regional Hospital |
2012-03 | PHASE3 |
| NCT02029573 | COMPLETED | Glioblastoma Multiforme |
King Fahad Medical City |
2014-01-01 | PHASE2 |
| NCT02029573 | COMPLETED | Glioblastoma Multiforme |
King Fahad Medical City |
2014-01-01 | PHASE2 |
| NCT02522117 | COMPLETED | Renal Insufficiency |
Instituto Mexicano del Seguro Social |
2015-08 | PHASE3 |
| NCT01720719 | UNKNOWN | Fatty Liver; Dyslipidemias; Diabetes Mellitus |
Xin Gao |
2013-05 | PHASE4 |
| NCT01720719 | UNKNOWN | Fatty Liver; Dyslipidemias; Diabetes Mellitus |
Xin Gao |
2013-05 | PHASE4 |
| NCT02522117 | COMPLETED | Renal Insufficiency |
Instituto Mexicano del Seguro Social |
2015-08 | PHASE3 |
| NCT03657472 | COMPLETED | Hypertension; Hyperlipidemia |
HK inno.N Corporation |
2016-09-19 | PHASE1 |
| NCT03657472 | COMPLETED | Hypertension; Hyperlipidemia |
HK inno.N Corporation |
2016-09-19 | PHASE1 |
| NCT01956201 | UNKNOWN | Mixed Hyperlipidemia |
Chong Kun Dang Pharmaceutical |
2013-12 | PHASE3 |
| NCT01956201 | UNKNOWN | Mixed Hyperlipidemia |
Chong Kun Dang Pharmaceutical |
2013-12 | PHASE3 |
| NCT02659397 | COMPLETED | Hyperlipidemia |
Esperion Therapeutics, Inc. |
2015-12 | PHASE2 |
| NCT02411903 | UNKNOWN | Cerebral Infarction; Clopidogrel,Poor Metabolism of (Disorder) |
The Third Affiliated Hospital of Guangzhou Medical University |
2015-03 | PHASE4 |
| NCT02411903 | UNKNOWN | Cerebral Infarction; Clopidogrel,Poor Metabolism of (Disorder) |
The Third Affiliated Hospital of Guangzhou Medical University |
2015-03 | PHASE4 |
| NCT02496962 | UNKNOWN | Sleep Deprivation |
Shi Yang |
2015-07 | |
| NCT01870804 | COMPLETED | Acute Coronary Syndrome |
Centro Cardiopatici Toscani |
2013-05 | PHASE4 |
| NCT02659397 | COMPLETED | Hyperlipidemia |
Esperion Therapeutics, Inc. |
2015-12 | PHASE2 |
| NCT02496962 | UNKNOWN | Sleep Deprivation |
Shi Yang |
2015-07 | |
| NCT01870804 | COMPLETED | Acute Coronary Syndrome |
Centro Cardiopatici Toscani |
2013-05 | PHASE4 |
| NCT02550288 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2015-09-29 | PHASE3 |
| NCT02550288 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2015-09-29 | PHASE3 |
| NCT02749578 | COMPLETED | Healthy |
Madrigal Pharmaceuticals, Inc. |
2016-04 | PHASE1 |
| NCT02749578 | COMPLETED | Healthy |
Madrigal Pharmaceuticals, Inc. |
2016-04 | PHASE1 |
| NCT02609711 | UNKNOWN | Healthy Male Subjects |
Ahn-Gook Pharmaceuticals Co.,Ltd |
2015-11 | PHASE1 |
| NCT01442428 | WITHDRAWN | Immune Reconstitution Inflammatory Syndrome; Immune Reconstitution Syndrome; Tuberculosis; HIV-infection/Aids |
University of Minnesota |
2014-01 | PHASE2; PHASE3 |
| NCT02609711 | UNKNOWN | Healthy Male Subjects |
Ahn-Gook Pharmaceuticals Co.,Ltd |
2015-11 | PHASE1 |
| NCT02641899 | COMPLETED | Healthy |
Intarcia Therapeutics |
2015-12 | PHASE1 |
| NCT01442428 | WITHDRAWN | Immune Reconstitution Inflammatory Syndrome; Immune Reconstitution Syndrome; Tuberculosis; HIV-infection/Aids |
University of Minnesota |
2014-01 | PHASE2; PHASE3 |
| NCT02641899 | COMPLETED | Healthy |
Intarcia Therapeutics |
2015-12 | PHASE1 |
| NCT02685462 | COMPLETED | Healthy |
Tobira Therapeutics, Inc. |
2016-01-31 | PHASE1 |
| NCT02685462 | COMPLETED | Healthy |
Tobira Therapeutics, Inc. |
2016-01-31 | PHASE1 |
| NCT02800902 | COMPLETED | Chronic Periodontitis |
Government Dental College and Research Institute, Bangalore |
2015-05 | PHASE2; PHASE3 |
| NCT02800902 | COMPLETED | Chronic Periodontitis |
Government Dental College and Research Institute, Bangalore |
2015-05 | PHASE2; PHASE3 |
| NCT02614352 | UNKNOWN | Healthy Male Subjects |
Ahn-Gook Pharmaceuticals Co.,Ltd |
PHASE1 | |
| NCT02614352 | UNKNOWN | Healthy Male Subjects |
Ahn-Gook Pharmaceuticals Co.,Ltd |
PHASE1 | |
| NCT02350959 | UNKNOWN | Plaque |
National Health Insurance Service Ilsan Hospital |
2015-01 | PHASE4 |
| NCT02350959 | UNKNOWN | Plaque |
National Health Insurance Service Ilsan Hospital |
2015-01 | PHASE4 |
| NCT02380625 | UNKNOWN | Ebola Virus Disease |
Clinical Research Management, Inc. |
2015-04 | PHASE1; PHASE2 |
| NCT02380625 | UNKNOWN | Ebola Virus Disease |
Clinical Research Management, Inc. |
2015-04 | PHASE1; PHASE2 |
| NCT01648829 | UNKNOWN | Coronary Artery Disease |
University of Roma La Sapienza |
2014-01 | PHASE4 |
| NCT02286544 | COMPLETED | Myocardial Infarction; Inflammation; Acute Coronary Syndrome (ACS); Reperfusion Injury |
Karolinska Institutet |
2014-10 | PHASE1 |
| NCT01987310 | WITHDRAWN | Non Alcoholic Fatty Liver Disease |
Sheba Medical Center |
2015-12 | |
| NCT01648829 | UNKNOWN | Coronary Artery Disease |
University of Roma La Sapienza |
2014-01 | PHASE4 |
| NCT01987310 | WITHDRAWN | Non Alcoholic Fatty Liver Disease |
Sheba Medical Center |
2015-12 | |
| NCT02227784 | TERMINATED | Hyperlipidemia |
Eli Lilly and Company |
2014-10 | PHASE3 |
| NCT02227784 | TERMINATED | Hyperlipidemia |
Eli Lilly and Company |
2014-10 | PHASE3 |
| NCT02114099 | UNKNOWN | Kawasaki Disease; Aneurysm, Coronary |
National Taiwan University Hospital |
2007-06 | PHASE2 |
| NCT02114099 | UNKNOWN | Kawasaki Disease; Aneurysm, Coronary |
National Taiwan University Hospital |
2007-06 | PHASE2 |
| NCT02286544 | COMPLETED | Myocardial Infarction; Inflammation; Acute Coronary Syndrome (ACS); Reperfusion Injury |
Karolinska Institutet |
2014-10 | PHASE1 |
| NCT02135029 | COMPLETED | Hyperlipidemia |
Pfizer |
2014-06 | PHASE3 |
| NCT01733953 | COMPLETED | Cardiovascular Disease; Childhood ALL; Childhood NHL |
University of Minnesota |
2012-11 | PHASE2 |
| NCT01733953 | COMPLETED | Cardiovascular Disease; Childhood ALL; Childhood NHL |
University of Minnesota |
2012-11 | PHASE2 |
| NCT02135029 | COMPLETED | Hyperlipidemia |
Pfizer |
2014-06 | PHASE3 |
| NCT01322711 | UNKNOWN | Type 2 Diabetes Mellitus; Hypercholesterolemia |
University of Roma La Sapienza |
2011-03 | PHASE4 |
| NCT02566187 | COMPLETED | Hypertension; Hyperlipidemia |
Boryung Pharmaceutical Co., Ltd |
2015-08 | PHASE1 |
| NCT01322711 | UNKNOWN | Type 2 Diabetes Mellitus; Hypercholesterolemia |
University of Roma La Sapienza |
2011-03 | PHASE4 |
| NCT02254824 | UNKNOWN | Hypertension |
Chinese Academy of Medical Sciences, Fuwai Hospital |
2013-10 | PHASE4 |
| NCT01503671 | UNKNOWN | Heart Failure |
National Taiwan University Hospital |
2011-11 | PHASE4 |
| NCT02566187 | COMPLETED | Hypertension; Hyperlipidemia |
Boryung Pharmaceutical Co., Ltd |
2015-08 | PHASE1 |
| NCT02254824 | UNKNOWN | Hypertension |
Chinese Academy of Medical Sciences, Fuwai Hospital |
2013-10 | PHASE4 |
| NCT01503671 | UNKNOWN | Heart Failure |
National Taiwan University Hospital |
2011-11 | PHASE4 |
| NCT01697735 | TERMINATED | Dyslipidemias |
Wenzhou Medical University |
2012-09 | PHASE4 |
| NCT01697735 | TERMINATED | Dyslipidemias |
Wenzhou Medical University |
2012-09 | PHASE4 |
| NCT02612792 | COMPLETED | Furcation Defects |
Government Dental College and Research Institute, Bangalore |
2014-12 | PHASE2; PHASE3 |
| NCT02612792 | COMPLETED | Furcation Defects |
Government Dental College and Research Institute, Bangalore |
2014-12 | PHASE2; PHASE3 |
| NCT00979758 | COMPLETED | Myocardial Infarction; Stem Cell Transplantation; Angioplasty, Transluminal, Percutaneous Coronary |
Chinese Academy of Medical Sciences, Fuwai Hospital |
2009-01 | PHASE2 |
| NCT01299194 | COMPLETED | BRONCHIECTASIS |
University of Edinburgh |
2010-11 | PHASE4 |
| NCT01543555 | COMPLETED | Myocardial Infarction; Peripheral Vascular Disease; Aortic Aneurism |
Hospital do Coracao |
2012-11 | PHASE3 |
| NCT00979758 | COMPLETED | Myocardial Infarction; Stem Cell Transplantation; Angioplasty, Transluminal, Percutaneous Coronary |
Chinese Academy of Medical Sciences, Fuwai Hospital |
2009-01 | PHASE2 |
| NCT01543555 | COMPLETED | Myocardial Infarction; Peripheral Vascular Disease; Aortic Aneurism |
Hospital do Coracao |
2012-11 | PHASE3 |
| NCT01544751 | UNKNOWN | Nonalcoholic Fatty Liver Disease (NAFLD) |
Prof Antonino Belfiore |
2011-09 | |
| NCT01544751 | UNKNOWN | Nonalcoholic Fatty Liver Disease (NAFLD) |
Prof Antonino Belfiore |
2011-09 | |
| NCT01299194 | COMPLETED | BRONCHIECTASIS |
University of Edinburgh |
2010-11 | PHASE4 |
| NCT02157337 | COMPLETED | Aortic Surgery; Acute Kidney Injury |
Yonsei University |
2014-03-12 | PHASE4 |
| NCT02157337 | COMPLETED | Aortic Surgery; Acute Kidney Injury |
Yonsei University |
2014-03-12 | PHASE4 |
| NCT02516111 | COMPLETED | Chronic Periodontitis |
Government Dental College and Research Institute, Bangalore |
2014-09 | PHASE2; PHASE3 |
| NCT02600520 | COMPLETED | Chronic Periodontitis |
Government Dental College and Research Institute, Bangalore |
2014-11 | PHASE2; PHASE3 |
| NCT02600520 | COMPLETED | Chronic Periodontitis |
Government Dental College and Research Institute, Bangalore |
2014-11 | PHASE2; PHASE3 |
| NCT02516111 | COMPLETED | Chronic Periodontitis |
Government Dental College and Research Institute, Bangalore |
2014-09 | PHASE2; PHASE3 |
| NCT02243098 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2014-09-16 | PHASE1 |
| NCT02243098 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2014-09-16 | PHASE1 |
| NCT00818103 | UNKNOWN | Multiple Sclerosis |
Sun Yat-sen University |
2006-01 | |
| NCT02055976 | COMPLETED | Hypercholesterolemia |
Pfizer |
2014-03 | PHASE2 |
| NCT00818103 | UNKNOWN | Multiple Sclerosis |
Sun Yat-sen University |
2006-01 | |
| NCT02055976 | COMPLETED | Hypercholesterolemia |
Pfizer |
2014-03 | PHASE2 |
| NCT01255852 | COMPLETED | CVD |
Jinling Hospital, China |
2011-01 | PHASE4 |
| NCT00663234 | TERMINATED | HIV Infections; Hyperlipidemia |
International Maternal Pediatric Adolescent AIDS Clinical Trials Group |
2009-08 | PHASE1; PHASE2 |
| NCT01255852 | COMPLETED | CVD |
Jinling Hospital, China |
2011-01 | PHASE4 |
| NCT00663234 | TERMINATED | HIV Infections; Hyperlipidemia |
International Maternal Pediatric Adolescent AIDS Clinical Trials Group |
2009-08 | PHASE1; PHASE2 |
| NCT01220973 | COMPLETED | Prostate Cancer |
Rutgers, The State University of New Jersey |
2009-02 | PHASE2 |
| NCT01220973 | COMPLETED | Prostate Cancer |
Rutgers, The State University of New Jersey |
2009-02 | PHASE2 |
| NCT02681653 | COMPLETED | Septic Shock |
Sanjay Gandhi Postgraduate Institute of Medical Sciences |
2012-01 | |
| NCT02681653 | COMPLETED | Septic Shock |
Sanjay Gandhi Postgraduate Institute of Medical Sciences |
2012-01 | |
| NCT00791648 | COMPLETED | Acute Kidney Injury; Post-Operative Delirium; Icu Delirium; Acute Renal Failure; Delirium |
Vanderbilt University Medical Center |
2009-07 | |
| NCT00791648 | COMPLETED | Acute Kidney Injury; Post-Operative Delirium; Icu Delirium; Acute Renal Failure; Delirium |
Vanderbilt University Medical Center |
2009-07 | |
| NCT01780740 | COMPLETED | Disorder; Heart, Functional, Postoperative, Cardiac Surgery; Cardiac Insufficiency Following Cardiac Surgery; Atrial Fibrillation; Ischaemia-reperfusion Injury |
University of Oxford |
2012-01 | PHASE4 |
| NCT01665235 | UNKNOWN | Blood Pressure Variability; Intracranial Artery Stenosis |
RenJi Hospital |
2012-08 | |
| NCT03009097 | COMPLETED | Chronic Periaortitis; Intrabony Periodontal Defect |
Kamineni Institute of Dental Sciences |
2013-04 | PHASE4 |
| NCT02023892 | UNKNOWN | Endothelium; Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Sun Yat-sen University |
2014-06 | PHASE4 |
| NCT01780740 | COMPLETED | Disorder; Heart, Functional, Postoperative, Cardiac Surgery; Cardiac Insufficiency Following Cardiac Surgery; Atrial Fibrillation; Ischaemia-reperfusion Injury |
University of Oxford |
2012-01 | PHASE4 |
| NCT01665235 | UNKNOWN | Blood Pressure Variability; Intracranial Artery Stenosis |
RenJi Hospital |
2012-08 | |
| NCT02023892 | UNKNOWN | Endothelium; Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Sun Yat-sen University |
2014-06 | PHASE4 |
| NCT03009097 | COMPLETED | Chronic Periaortitis; Intrabony Periodontal Defect |
Kamineni Institute of Dental Sciences |
2013-04 | PHASE4 |
| NCT01544309 | COMPLETED | Hypercholesterolemia With Concomitant Type 2 Diabetes |
Listen Trial Group |
2012-03 | |
| NCT01570530 | TERMINATED | Atrial Fibrillation |
Fundación General Universidad de Valladolid |
2011-01 | PHASE3 |
| NCT01953328 | COMPLETED | Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events |
Amgen |
2013-10 | PHASE3 |
| NCT01570530 | TERMINATED | Atrial Fibrillation |
Fundación General Universidad de Valladolid |
2011-01 | PHASE3 |
| NCT01953328 | COMPLETED | Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events |
Amgen |
2013-10 | PHASE3 |
| NCT00979940 | TERMINATED | Coronary Artery Disease |
Indiana University |
2008-11 | |
| NCT00979940 | TERMINATED | Coronary Artery Disease |
Indiana University |
2008-11 | |
| NCT01544309 | COMPLETED | Hypercholesterolemia With Concomitant Type 2 Diabetes |
Listen Trial Group |
2012-03 | |
| NCT00375518 | COMPLETED | Thoracic Surgery |
Memorial Sloan Kettering Cancer Center |
2006-07 | |
| NCT02089061 | COMPLETED | Acute Coronary Syndromes |
Bristol-Myers Squibb |
2014-03 | PHASE1 |
| NCT00375518 | COMPLETED | Thoracic Surgery |
Memorial Sloan Kettering Cancer Center |
2006-07 | |
| NCT02089061 | COMPLETED | Acute Coronary Syndromes |
Bristol-Myers Squibb |
2014-03 | PHASE1 |
| NCT00768638 | COMPLETED | Chronic Kidney Disease |
Laval University |
2008-10 | PHASE4 |
| NCT00805311 | TERMINATED | Carotid Artery Stenosis; Atherosclerosis; Stroke |
Russian Cardiology Research and Production Center |
2009-04 | PHASE4 |
| NCT00768638 | COMPLETED | Chronic Kidney Disease |
Laval University |
2008-10 | PHASE4 |
| NCT00805311 | TERMINATED | Carotid Artery Stenosis; Atherosclerosis; Stroke |
Russian Cardiology Research and Production Center |
2009-04 | PHASE4 |
| NCT02113540 | UNKNOWN | Contrast Induced Nephropathy |
Isfahan University of Medical Sciences |
2012-01 | PHASE3 |
| NCT02113540 | UNKNOWN | Contrast Induced Nephropathy |
Isfahan University of Medical Sciences |
2012-01 | PHASE3 |
| NCT02066207 | COMPLETED | Dyslipidemia (Fredrickson Type Ⅱa); Dyslipidemia (Fredrickson Type Ⅱb) |
Chong Kun Dang Pharmaceutical |
2014-03-18 | PHASE1 |
| NCT02066207 | COMPLETED | Dyslipidemia (Fredrickson Type Ⅱa); Dyslipidemia (Fredrickson Type Ⅱb) |
Chong Kun Dang Pharmaceutical |
2014-03-18 | PHASE1 |
| NCT02093390 | COMPLETED | Prostate Cancer; Endometriosis |
Millennium Pharmaceuticals, Inc. |
2014-03 | PHASE1 |
| NCT02093390 | COMPLETED | Prostate Cancer; Endometriosis |
Millennium Pharmaceuticals, Inc. |
2014-03 | PHASE1 |
| NCT02084069 | COMPLETED | Heart Valve Diseases |
Urmia University of Medical Sciences |
2013-01 | PHASE3 |
| NCT01730040 | COMPLETED | Hypercholesterolemia |
Regeneron Pharmaceuticals |
2012-10 | PHASE3 |
| NCT02084069 | COMPLETED | Heart Valve Diseases |
Urmia University of Medical Sciences |
2013-01 | PHASE3 |
| NCT01730040 | COMPLETED | Hypercholesterolemia |
Regeneron Pharmaceuticals |
2012-10 | PHASE3 |
| NCT02080455 | COMPLETED | Effect of Atorvastatin on the Pharmacokinetics of Lomitapide |
Aegerion Pharmaceuticals, Inc. |
2014-01-27 | PHASE1 |
| NCT02080455 | COMPLETED | Effect of Atorvastatin on the Pharmacokinetics of Lomitapide |
Aegerion Pharmaceuticals, Inc. |
2014-01-27 | PHASE1 |
| NCT01043380 | COMPLETED | Hypercholesterolemia; Coronary Artery Disease |
Kumamoto University |
2010-01 | PHASE4 |
| NCT01043380 | COMPLETED | Hypercholesterolemia; Coronary Artery Disease |
Kumamoto University |
2010-01 | PHASE4 |
| NCT01526460 | COMPLETED | Platelet Dysfunction |
IRCCS San Raffaele |
2011-08 | PHASE2 |
| NCT01526460 | COMPLETED | Platelet Dysfunction |
IRCCS San Raffaele |
2011-08 | PHASE2 |
| NCT00965185 | COMPLETED | Cardiovascular Disease; HIV; Atherosclerosis; Inflammation; Statins, HMG-CoA; HIV Infections |
Massachusetts General Hospital |
2009-09 | |
| NCT01929135 | COMPLETED | Chronic Periodontitis |
Universidad de los Andes, Chile |
2013-05 | PHASE2 |
| NCT00965185 | COMPLETED | Cardiovascular Disease; HIV; Atherosclerosis; Inflammation; Statins, HMG-CoA; HIV Infections |
Massachusetts General Hospital |
2009-09 | |
| NCT01929135 | COMPLETED | Chronic Periodontitis |
Universidad de los Andes, Chile |
2013-05 | PHASE2 |
| NCT02225834 | COMPLETED | Ischemic Stroke |
University of Palermo |
2011-11 | PHASE4 |
| NCT02225834 | COMPLETED | Ischemic Stroke |
University of Palermo |
2011-11 | PHASE4 |
| NCT02432040 | COMPLETED | Psoriasis |
Philippine Dermatological Society |
2013-02 | PHASE2 |
| NCT01236365 | COMPLETED | Diabetes Mellitus, Insulin-Dependent; Hypercholesterolemia |
Nemours Children's Clinic |
2010-10 | PHASE3 |
| NCT01236365 | COMPLETED | Diabetes Mellitus, Insulin-Dependent; Hypercholesterolemia |
Nemours Children's Clinic |
2010-10 | PHASE3 |
| NCT01820767 | COMPLETED | Chronic Kidney Disease |
Ricardo Mouzo Mirco |
2012-08 | PHASE3 |
| NCT01820767 | COMPLETED | Chronic Kidney Disease |
Ricardo Mouzo Mirco |
2012-08 | PHASE3 |
| NCT02432040 | COMPLETED | Psoriasis |
Philippine Dermatological Society |
2013-02 | PHASE2 |
| NCT00920101 | UNKNOWN | Atherosclerosis; Inflammation |
National Defense Medical College, Japan |
2009-06 | PHASE4 |
| NCT00920101 | UNKNOWN | Atherosclerosis; Inflammation |
National Defense Medical College, Japan |
2009-06 | PHASE4 |
| NCT01023607 | COMPLETED | Coronary Artery Disease; Hyperlipidemia |
Harbin Medical University |
2009-12 | PHASE4 |
| NCT01023607 | COMPLETED | Coronary Artery Disease; Hyperlipidemia |
Harbin Medical University |
2009-12 | PHASE4 |
| NCT01779453 | COMPLETED | Hypercholesterolemia |
Esperion Therapeutics, Inc. |
2012-12 | PHASE2 |
| NCT01779453 | COMPLETED | Hypercholesterolemia |
Esperion Therapeutics, Inc. |
2012-12 | PHASE2 |
| NCT01071993 | TERMINATED | Nephropathy |
University of Oklahoma |
2010-03 | |
| NCT01071993 | TERMINATED | Nephropathy |
University of Oklahoma |
2010-03 | |
| NCT00292201 | TERMINATED | Asthma |
Queen's University |
2006-02 | PHASE2 |
| NCT00292201 | TERMINATED | Asthma |
Queen's University |
2006-02 | PHASE2 |
| NCT01692717 | COMPLETED | Healthy Subjects |
Azidus Brasil |
2013-02-28 | PHASE1 |
| NCT01692717 | COMPLETED | Healthy Subjects |
Azidus Brasil |
2013-02-28 | PHASE1 |
| NCT01842256 | COMPLETED | Essential Hypertension; Hyperlipidemia |
Chong Kun Dang Pharmaceutical |
2013-04 | PHASE1 |
| NCT01842256 | COMPLETED | Essential Hypertension; Hyperlipidemia |
Chong Kun Dang Pharmaceutical |
2013-04 | PHASE1 |
| NCT01442987 | COMPLETED | Hypertension; Hyperlipidemia |
Hanmi Pharmaceutical Company Limited |
2011-05 | PHASE3 |
| NCT01442987 | COMPLETED | Hypertension; Hyperlipidemia |
Hanmi Pharmaceutical Company Limited |
2011-05 | PHASE3 |
| NCT01795937 | COMPLETED | Healthy |
Boehringer Ingelheim |
2013-02 | PHASE1 |
| NCT01795937 | COMPLETED | Healthy |
Boehringer Ingelheim |
2013-02 | PHASE1 |
| NCT01555632 | WITHDRAWN | Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer |
University of Nebraska |
2012-03 | |
| NCT01555632 | WITHDRAWN | Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer |
University of Nebraska |
2012-03 | |
| NCT01646307 | UNKNOWN | Focus of Study |
Beijing Anzhen Hospital |
2012-01 | PHASE4 |
| NCT01646307 | UNKNOWN | Focus of Study |
Beijing Anzhen Hospital |
2012-01 | PHASE4 |
| NCT01765023 | COMPLETED | Healthy |
HK inno.N Corporation |
2012-10 | PHASE1 |
| NCT01518231 | UNKNOWN | Stroke |
Zhejiang Hospital |
2012-01 | PHASE1 |
| NCT01765023 | COMPLETED | Healthy |
HK inno.N Corporation |
2012-10 | PHASE1 |
| NCT01518231 | UNKNOWN | Stroke |
Zhejiang Hospital |
2012-01 | PHASE1 |
| NCT01806324 | COMPLETED | Hypertension; Hyperlipidemia |
HanAll BioPharma Co., Ltd. |
2012-04 | PHASE1 |
| NCT00185731 | COMPLETED | Leukemia; Lymphoma, Non-Hodgkin |
Dean Felsher |
2005-04 | PHASE2 |
| NCT01806324 | COMPLETED | Hypertension; Hyperlipidemia |
HanAll BioPharma Co., Ltd. |
2012-04 | PHASE1 |
| NCT00917527 | UNKNOWN | Coronary Heart Disease |
Yonsei University |
2009-06 | PHASE4 |
| NCT00185731 | COMPLETED | Leukemia; Lymphoma, Non-Hodgkin |
Dean Felsher |
2005-04 | PHASE2 |
| NCT00917527 | UNKNOWN | Coronary Heart Disease |
Yonsei University |
2009-06 | PHASE4 |
| NCT00637481 | COMPLETED | Atypical Ductal Breast Hyperplasia; Breast Cancer; Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ |
National Cancer Institute (NCI) |
2008-03 | PHASE1 |
| NCT00637481 | COMPLETED | Atypical Ductal Breast Hyperplasia; Breast Cancer; Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ |
National Cancer Institute (NCI) |
2008-03 | PHASE1 |
| NCT01154036 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2010-07 | PHASE3 |
| NCT01154036 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2010-07 | PHASE3 |
| NCT00616772 | COMPLETED | Coronary Artery Disease; Coronary Heart Disease; Dyslipidemia |
AbbVie (prior sponsor, Abbott) |
2008-02 | PHASE3 |
| NCT00616772 | COMPLETED | Coronary Artery Disease; Coronary Heart Disease; Dyslipidemia |
AbbVie (prior sponsor, Abbott) |
2008-02 | PHASE3 |
| NCT01572623 | UNKNOWN | Carotid Stenosis |
Campus Bio-Medico University |
2011-07 | PHASE4 |
| NCT01572623 | UNKNOWN | Carotid Stenosis |
Campus Bio-Medico University |
2011-07 | PHASE4 |
| NCT01372839 | UNKNOWN | Myocardial Infarction; Unstable Angina |
Xijing Hospital |
2010-07 | PHASE4 |
| NCT01372839 | UNKNOWN | Myocardial Infarction; Unstable Angina |
Xijing Hospital |
2010-07 | PHASE4 |
| NCT01341730 | TERMINATED | Atherosclerosis; Coronary Artery Disease |
The Catholic University of Korea |
2011-06 | PHASE4 |
| NCT00491751 | TERMINATED | Peripheral Arterial Disease |
Boston University |
2004-05 | PHASE1 |
| NCT00491751 | TERMINATED | Peripheral Arterial Disease |
Boston University |
2004-05 | PHASE1 |
| NCT01341730 | TERMINATED | Atherosclerosis; Coronary Artery Disease |
The Catholic University of Korea |
2011-06 | PHASE4 |
| NCT01370603 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2011-09 | PHASE3 |
| NCT01370603 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2011-09 | PHASE3 |
| NCT01350141 | COMPLETED | Hypercholesterolemia; Dyslipidemia |
Pfizer |
2011-06 | PHASE2 |
| NCT01350141 | COMPLETED | Hypercholesterolemia; Dyslipidemia |
Pfizer |
2011-06 | PHASE2 |
| NCT01386853 | UNKNOWN | Hyperlipidemia |
Tai Tien Pharmaceuticals Co., Ltd. |
2011-07 | PHASE3 |
| NCT01386853 | UNKNOWN | Hyperlipidemia |
Tai Tien Pharmaceuticals Co., Ltd. |
2011-07 | PHASE3 |
| NCT01342211 | COMPLETED | Hypercholesterolemia; Dyslipidemia |
Pfizer |
2011-07 | PHASE2 |
| NCT00700037 | COMPLETED | Acute Coronary Syndrome; Atherosclerosis; Dyslipidemia |
Wakayama Medical University |
2009-08 | PHASE4 |
| NCT00700037 | COMPLETED | Acute Coronary Syndrome; Atherosclerosis; Dyslipidemia |
Wakayama Medical University |
2009-08 | PHASE4 |
| NCT01342211 | COMPLETED | Hypercholesterolemia; Dyslipidemia |
Pfizer |
2011-07 | PHASE2 |
| NCT01213498 | COMPLETED | Nephropathy; Cardiovascular Diseases |
Erling Bjerregaard Pedersen |
2010-05 | PHASE2 |
| NCT00490698 | COMPLETED | Kidney Cancer; Renal Cell Carcinoma |
M.D. Anderson Cancer Center |
2006-10 | PHASE2 |
| NCT01213498 | COMPLETED | Nephropathy; Cardiovascular Diseases |
Erling Bjerregaard Pedersen |
2010-05 | PHASE2 |
| NCT00490698 | COMPLETED | Kidney Cancer; Renal Cell Carcinoma |
M.D. Anderson Cancer Center |
2006-10 | PHASE2 |
| NCT01288443 | COMPLETED | Hypercholesterolemia |
Sanofi |
2011-01 | PHASE2 |
| NCT01335048 | COMPLETED | Stable Angina |
Ospedale Misericordia e Dolce |
2011-04 | PHASE4 |
| NCT01335048 | COMPLETED | Stable Angina |
Ospedale Misericordia e Dolce |
2011-04 | PHASE4 |
| NCT00579098 | COMPLETED | Atrial Fibrillation; Arrhythmia; Inflammation; Endothelial Dysfunction |
Mayo Clinic |
2007-12 | PHASE4 |
| NCT00579098 | COMPLETED | Atrial Fibrillation; Arrhythmia; Inflammation; Endothelial Dysfunction |
Mayo Clinic |
2007-12 | PHASE4 |
| NCT01288443 | COMPLETED | Hypercholesterolemia |
Sanofi |
2011-01 | PHASE2 |
| NCT01447797 | COMPLETED | Healthy |
Hanmi Pharmaceutical Company Limited |
2011-09 | PHASE1 |
| NCT01491256 | UNKNOWN | Acute Coronary Syndrome |
The Korean Society of Circulation |
2010-02 | |
| NCT01279590 | COMPLETED | Myalgia; Hypercholesterolemia; Hyperlipidemia |
Furiex Pharmaceuticals, Inc |
2011-03 | PHASE2 |
| NCT01447797 | COMPLETED | Healthy |
Hanmi Pharmaceutical Company Limited |
2011-09 | PHASE1 |
| NCT01491256 | UNKNOWN | Acute Coronary Syndrome |
The Korean Society of Circulation |
2010-02 | |
| NCT01279590 | COMPLETED | Myalgia; Hypercholesterolemia; Hyperlipidemia |
Furiex Pharmaceuticals, Inc |
2011-03 | PHASE2 |
| NCT01293097 | COMPLETED | Non-ST Segment Elevation Myocardial Infarction; Unstable Angina Pectoris; Stable Angina Pectoris |
Peking University First Hospital |
2010-06 | PHASE4 |
| NCT01293097 | COMPLETED | Non-ST Segment Elevation Myocardial Infarction; Unstable Angina Pectoris; Stable Angina Pectoris |
Peking University First Hospital |
2010-06 | PHASE4 |
| NCT02292069 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2011-09 | PHASE1 |
| NCT02292069 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2011-09 | PHASE1 |
| NCT01259284 | TERMINATED | Advanced Cancers |
M.D. Anderson Cancer Center |
2011-01 | PHASE2; PHASE3 |
| NCT01259284 | TERMINATED | Advanced Cancers |
M.D. Anderson Cancer Center |
2011-01 | PHASE2; PHASE3 |
| NCT00965055 | TERMINATED | High Cholesterol; Coronary Artery Disease |
University of California, San Diego |
2009-09 | PHASE3 |
| NCT00965055 | TERMINATED | High Cholesterol; Coronary Artery Disease |
University of California, San Diego |
2009-09 | PHASE3 |
| NCT01112670 | COMPLETED | Healthy |
University of Colorado, Denver |
2009-11 | PHASE4 |
| NCT01363999 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2011-06 | PHASE1 |
| NCT01112670 | COMPLETED | Healthy |
University of Colorado, Denver |
2009-11 | PHASE4 |
| NCT01363999 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2011-06 | PHASE1 |
| NCT01105975 | COMPLETED | Dyslipidemia |
Eli Lilly and Company |
2010-04 | PHASE2 |
| NCT00609063 | COMPLETED | Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases |
Hartford Hospital |
2008-01 | |
| NCT00620542 | COMPLETED | Coronary Atherosclerosis |
AstraZeneca |
2008-01 | PHASE3 |
| NCT01105975 | COMPLETED | Dyslipidemia |
Eli Lilly and Company |
2010-04 | PHASE2 |
| NCT00620542 | COMPLETED | Coronary Atherosclerosis |
AstraZeneca |
2008-01 | PHASE3 |
| NCT01214746 | COMPLETED | Cardiovascular Diseases; Nephropathy |
Regional Hospital Holstebro |
2010-05 | PHASE2 |
| NCT01214746 | COMPLETED | Cardiovascular Diseases; Nephropathy |
Regional Hospital Holstebro |
2010-05 | PHASE2 |
| NCT00609063 | COMPLETED | Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases |
Hartford Hospital |
2008-01 | |
| NCT00756886 | COMPLETED | Arrhythmia |
University of Alabama at Birmingham |
2008-09 | |
| NCT01332747 | COMPLETED | Hyperlipidemia |
Jamia Hamdard University |
2010-05 | PHASE2 |
| NCT01332747 | COMPLETED | Hyperlipidemia |
Jamia Hamdard University |
2010-05 | PHASE2 |
| NCT00756886 | COMPLETED | Arrhythmia |
University of Alabama at Birmingham |
2008-09 | |
| NCT00862251 | COMPLETED | Cardiovascular Disorder; Diabetes Mellitus |
Organon and Co |
2009-04 | PHASE3 |
| NCT00862251 | COMPLETED | Cardiovascular Disorder; Diabetes Mellitus |
Organon and Co |
2009-04 | PHASE3 |
| NCT01163851 | COMPLETED | Hypercholesterolemia; Dyslipidemia |
Pfizer |
2010-07 | PHASE1 |
| NCT01163851 | COMPLETED | Hypercholesterolemia; Dyslipidemia |
Pfizer |
2010-07 | PHASE1 |
| NCT01072097 | COMPLETED | Polycystic Ovary Syndrome |
University of Oulu |
2006-09 | |
| NCT01072097 | COMPLETED | Polycystic Ovary Syndrome |
University of Oulu |
2006-09 | |
| NCT00914017 | UNKNOWN | Breast Cancer |
University of Vermont |
2005-01 | PHASE2 |
| NCT00664846 | COMPLETED | Stroke |
Peking Union Medical College Hospital |
2008-04 | |
| NCT00143741 | COMPLETED | End-Stage Kidney Disease |
University of Chicago |
2005-05 | PHASE1 |
| NCT00701220 | COMPLETED | Cardiovascular Disease; Cardiomyopathy; Heart Disease; Myocardial Disease; Myocardial Ischemia |
Philip Binkley |
2007-04 | PHASE4 |
| NCT00723320 | UNKNOWN | Atherosclerosis |
Ministry of Science and Technology of the People´s Republic of China |
2008-02 | |
| NCT00331565 | COMPLETED | Morbid Obesity |
University of Oslo School of Pharmacy |
2006-08 | PHASE4 |
| NCT00723320 | UNKNOWN | Atherosclerosis |
Ministry of Science and Technology of the People´s Republic of China |
2008-02 | |
| NCT00331565 | COMPLETED | Morbid Obesity |
University of Oslo School of Pharmacy |
2006-08 | PHASE4 |
| NCT00914017 | UNKNOWN | Breast Cancer |
University of Vermont |
2005-01 | PHASE2 |
| NCT00664846 | COMPLETED | Stroke |
Peking Union Medical College Hospital |
2008-04 | |
| NCT00143741 | COMPLETED | End-Stage Kidney Disease |
University of Chicago |
2005-05 | PHASE1 |
| NCT00701220 | COMPLETED | Cardiovascular Disease; Cardiomyopathy; Heart Disease; Myocardial Disease; Myocardial Ischemia |
Philip Binkley |
2007-04 | PHASE4 |
| NCT00153166 | COMPLETED | Arterial Occlusive Disease; Intermittent Claudication; Insulin Resistance |
Brigham and Women's Hospital |
2004-01 | PHASE2; PHASE3 |
| NCT01059864 | COMPLETED | Rheumatoid Arthritis |
Pfizer |
2010-02 | PHASE2 |
| NCT01059864 | COMPLETED | Rheumatoid Arthritis |
Pfizer |
2010-02 | PHASE2 |
| NCT00153166 | COMPLETED | Arterial Occlusive Disease; Intermittent Claudication; Insulin Resistance |
Brigham and Women's Hospital |
2004-01 | PHASE2; PHASE3 |
| NCT00289900 | COMPLETED | Mixed Hyperlipidemia |
Merck Sharp & Dohme LLC |
2006-01-24 | PHASE3 |
| NCT00289900 | COMPLETED | Mixed Hyperlipidemia |
Merck Sharp & Dohme LLC |
2006-01-24 | PHASE3 |
| NCT00910221 | COMPLETED | Acute Kidney Dysfunction |
Austin Health |
2008-03 | PHASE2; PHASE3 |
| NCT00910221 | COMPLETED | Acute Kidney Dysfunction |
Austin Health |
2008-03 | PHASE2; PHASE3 |
| NCT01138072 | COMPLETED | Infection, Human Immunodeficiency Virus |
GlaxoSmithKline |
2010-06 | PHASE1 |
| NCT01138072 | COMPLETED | Infection, Human Immunodeficiency Virus |
GlaxoSmithKline |
2010-06 | PHASE1 |
| NCT00529542 | COMPLETED | Polycystic Ovary Syndrome |
Milton S. Hershey Medical Center |
2004-12 | PHASE2 |
| NCT00529542 | COMPLETED | Polycystic Ovary Syndrome |
Milton S. Hershey Medical Center |
2004-12 | PHASE2 |
| NCT01096875 | COMPLETED | Coronary Artery Bypass Surgery; Elective Surgical Procedure |
Ankara University |
2010-02 | PHASE4 |
| NCT01257009 | COMPLETED | Stable Chronic Kidney Disease; Hypertension |
UMC Utrecht |
2009-08 | PHASE4 |
| NCT01257009 | COMPLETED | Stable Chronic Kidney Disease; Hypertension |
UMC Utrecht |
2009-08 | PHASE4 |
| NCT01096875 | COMPLETED | Coronary Artery Bypass Surgery; Elective Surgical Procedure |
Ankara University |
2010-02 | PHASE4 |
| NCT00772564 | COMPLETED | Myocardial Infarction |
Rambam Health Care Campus |
2008-08 | PHASE4 |
| NCT00772564 | COMPLETED | Myocardial Infarction |
Rambam Health Care Campus |
2008-08 | PHASE4 |
| NCT01050348 | COMPLETED | Acute Myocardial Infarction |
The Western Pennsylvania Hospital |
2009-06 | PHASE4 |
| NCT01058057 | UNKNOWN | Coronary Artery Disease; Coronary Angioplasty |
University Hospital, Motol |
2008-02 | PHASE3 |
| NCT01050348 | COMPLETED | Acute Myocardial Infarction |
The Western Pennsylvania Hospital |
2009-06 | PHASE4 |
| NCT01058057 | UNKNOWN | Coronary Artery Disease; Coronary Angioplasty |
University Hospital, Motol |
2008-02 | PHASE3 |
| NCT01111656 | COMPLETED | Relapsing-remitting Multiple Sclerosis |
Insel Gruppe AG, University Hospital Bern |
2007-03 | PHASE2 |
| NCT01115985 | COMPLETED | Healthy; Pharmacokinetics of Atorvastatin |
Astellas Pharma Inc |
2010-03 | PHASE1 |
| NCT01111656 | COMPLETED | Relapsing-remitting Multiple Sclerosis |
Insel Gruppe AG, University Hospital Bern |
2007-03 | PHASE2 |
| NCT01115985 | COMPLETED | Healthy; Pharmacokinetics of Atorvastatin |
Astellas Pharma Inc |
2010-03 | PHASE1 |
| NCT00615823 | COMPLETED | Hypertension, Pulmonary |
Chinese Academy of Medical Sciences, Fuwai Hospital |
2007-02 | PHASE2 |
| NCT00615823 | COMPLETED | Hypertension, Pulmonary |
Chinese Academy of Medical Sciences, Fuwai Hospital |
2007-02 | PHASE2 |
| NCT01299597 | COMPLETED | Sleep Disorders |
GlaxoSmithKline |
2010-01-18 | PHASE1 |
| NCT01299597 | COMPLETED | Sleep Disorders |
GlaxoSmithKline |
2010-01-18 | PHASE1 |
| NCT00987974 | COMPLETED | Ischemia Reperfusion Injury; Endothelial Dysfunction |
Radboud University Medical Center |
2009-09 | PHASE4 |
| NCT00987974 | COMPLETED | Ischemia Reperfusion Injury; Endothelial Dysfunction |
Radboud University Medical Center |
2009-09 | PHASE4 |
| NCT00902967 | UNKNOWN | Abdominal Surgery |
B. J. Medical College, Pune |
2009-07 | PHASE3 |
| NCT00703261 | COMPLETED | Atherosclerotic Vascular Disease |
Merck Sharp & Dohme LLC |
2008-08 | PHASE1 |
| NCT00902967 | UNKNOWN | Abdominal Surgery |
B. J. Medical College, Pune |
2009-07 | PHASE3 |
| NCT00620204 | UNKNOWN | Angina Pectoris, Variant |
Samsung Medical Center |
2008-01 | PHASE4 |
| NCT00620204 | UNKNOWN | Angina Pectoris, Variant |
Samsung Medical Center |
2008-01 | PHASE4 |
| NCT00065806 | COMPLETED | Lupus Erythematosus, Systemic |
Laura Schanberg |
2003-09 | PHASE3 |
| NCT00065806 | COMPLETED | Lupus Erythematosus, Systemic |
Laura Schanberg |
2003-09 | PHASE3 |
| NCT00703261 | COMPLETED | Atherosclerotic Vascular Disease |
Merck Sharp & Dohme LLC |
2008-08 | PHASE1 |
| NCT01200056 | COMPLETED | Coronary Disease; Ultrasonography, Interventional; Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Prof. Stephen Lee |
2007-08 | PHASE4 |
| NCT00640744 | UNKNOWN | Atherosclerosis |
Baylor College of Medicine |
2006-02 | PHASE4 |
| NCT01200056 | COMPLETED | Coronary Disease; Ultrasonography, Interventional; Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Prof. Stephen Lee |
2007-08 | PHASE4 |
| NCT00640744 | UNKNOWN | Atherosclerosis |
Baylor College of Medicine |
2006-02 | PHASE4 |
| NCT00718796 | COMPLETED | Cardiovascular Disease |
The Canadian College of Naturopathic Medicine |
2008-04 | PHASE3 |
| NCT00718796 | COMPLETED | Cardiovascular Disease |
The Canadian College of Naturopathic Medicine |
2008-04 | PHASE3 |
| NCT01499758 | COMPLETED | Healthy |
Ranbaxy Laboratories Limited |
2009-10 | PHASE1 |
| NCT01499758 | COMPLETED | Healthy |
Ranbaxy Laboratories Limited |
2009-10 | PHASE1 |
| NCT01073800 | COMPLETED | Myocardial Infarction; Stroke; Renal Failure |
University of Alberta |
2009-04 | PHASE2; PHASE3 |
| NCT01073800 | COMPLETED | Myocardial Infarction; Stroke; Renal Failure |
University of Alberta |
2009-04 | PHASE2; PHASE3 |
| NCT00404599 | UNKNOWN | Diabetes Mellitus; Hypertension |
Amsterdam UMC, location VUmc |
2007-02 | PHASE4 |
| NCT01285544 | COMPLETED | Dyslipidemia; Cardiovascular Disease; Hypercholesterolemia |
Seoul National University Hospital |
2008-09 | PHASE4 |
| NCT00404599 | UNKNOWN | Diabetes Mellitus; Hypertension |
Amsterdam UMC, location VUmc |
2007-02 | PHASE4 |
| NCT01285544 | COMPLETED | Dyslipidemia; Cardiovascular Disease; Hypercholesterolemia |
Seoul National University Hospital |
2008-09 | PHASE4 |
| NCT00463827 | COMPLETED | Asthma; COPD; Smoking |
NHS Greater Clyde and Glasgow |
2007-08 | PHASE2 |
| NCT00463827 | COMPLETED | Asthma; COPD; Smoking |
NHS Greater Clyde and Glasgow |
2007-08 | PHASE2 |
| NCT00094172 | COMPLETED | Multiple Sclerosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-05 | PHASE2 |
| NCT00739999 | COMPLETED | Pediatric Heterozygous Hypercholesterolemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2008-12 | PHASE1 |
| NCT00094172 | COMPLETED | Multiple Sclerosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-05 | PHASE2 |
| NCT00739999 | COMPLETED | Pediatric Heterozygous Hypercholesterolemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2008-12 | PHASE1 |
| NCT00889226 | COMPLETED | Hypercholesterolemia With Type2DM |
JW Pharmaceutical |
2008-04 | PHASE4 |
| NCT00889226 | COMPLETED | Hypercholesterolemia With Type2DM |
JW Pharmaceutical |
2008-04 | PHASE4 |
| NCT00335504 | COMPLETED | Colon Cancer; Precancerous Condition; Rectal Cancer |
National Cancer Institute (NCI) |
2006-03 | PHASE2 |
| NCT00734123 | UNKNOWN | Atherosclerosis; Cardiovascular Diseases |
Hospital Arnau de Vilanova |
2008-04 | PHASE4 |
| NCT01645410 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2009-03 | PHASE1 |
| NCT00734123 | UNKNOWN | Atherosclerosis; Cardiovascular Diseases |
Hospital Arnau de Vilanova |
2008-04 | PHASE4 |
| NCT01645410 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2009-03 | PHASE1 |
| NCT00335504 | COMPLETED | Colon Cancer; Precancerous Condition; Rectal Cancer |
National Cancer Institute (NCI) |
2006-03 | PHASE2 |
| NCT01041729 | COMPLETED | Peripheral Arterial Disease |
Hospital Universitario Getafe |
2008-01 | PHASE4 |
| NCT00535405 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2007-11 | PHASE3 |
| NCT00535405 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2007-11 | PHASE3 |
| NCT00960323 | COMPLETED | Healthy |
Mutual Pharmaceutical Company, Inc. |
2009-02 | PHASE1 |
| NCT00960323 | COMPLETED | Healthy |
Mutual Pharmaceutical Company, Inc. |
2009-02 | PHASE1 |
| NCT01041729 | COMPLETED | Peripheral Arterial Disease |
Hospital Universitario Getafe |
2008-01 | PHASE4 |
| NCT00728013 | UNKNOWN | Acute Coronary Syndrome |
Ministry of Science and Technology of the People´s Republic of China |
2006-12 | |
| NCT00808717 | COMPLETED | Myocardial Infarction; Angioplasty; Percutaneous Coronary |
Yonsei University |
2007-07 | PHASE4 |
| NCT00491400 | TERMINATED | Diabetes Mellitus; Metabolic Syndrome |
Boston University |
2005-09 | |
| NCT00172419 | COMPLETED | Hyperlipidemia |
National Taiwan University Hospital |
2007-03 | |
| NCT00808717 | COMPLETED | Myocardial Infarction; Angioplasty; Percutaneous Coronary |
Yonsei University |
2007-07 | PHASE4 |
| NCT00491400 | TERMINATED | Diabetes Mellitus; Metabolic Syndrome |
Boston University |
2005-09 | |
| NCT00361283 | COMPLETED | Inflammation |
University of Florida |
2004-06 | PHASE4 |
| NCT00172419 | COMPLETED | Hyperlipidemia |
National Taiwan University Hospital |
2007-03 | |
| NCT00728013 | UNKNOWN | Acute Coronary Syndrome |
Ministry of Science and Technology of the People´s Republic of China |
2006-12 | |
| NCT00361283 | COMPLETED | Inflammation |
University of Florida |
2004-06 | PHASE4 |
| NCT00491530 | COMPLETED | Mixed Dyslipidemia |
Abbott |
2007-06 | PHASE3 |
| NCT00252967 | TERMINATED | Atrial Fibrillation; Inflammation |
Emory University |
2005-10 | PHASE3 |
| NCT00491530 | COMPLETED | Mixed Dyslipidemia |
Abbott |
2007-06 | PHASE3 |
| NCT00252967 | TERMINATED | Atrial Fibrillation; Inflammation |
Emory University |
2005-10 | PHASE3 |
| NCT00559962 | COMPLETED | Hyperlipidemia |
Aegerion Pharmaceuticals, Inc. |
2007-10 | PHASE2 |
| NCT00442897 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2006-09 | PHASE4 |
| NCT01029522 | COMPLETED | Dyslipidemia |
Chong Kun Dang Pharmaceutical |
2008-08 | PHASE4 |
| NCT00442897 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2006-09 | PHASE4 |
| NCT00344019 | TERMINATED | Coronary Disease |
Beth Israel Deaconess Medical Center |
2006-05 | PHASE4 |
| NCT01029522 | COMPLETED | Dyslipidemia |
Chong Kun Dang Pharmaceutical |
2008-08 | PHASE4 |
| NCT00344019 | TERMINATED | Coronary Disease |
Beth Israel Deaconess Medical Center |
2006-05 | PHASE4 |
| NCT00559962 | COMPLETED | Hyperlipidemia |
Aegerion Pharmaceuticals, Inc. |
2007-10 | PHASE2 |
| NCT00627575 | COMPLETED | Epilepsy |
GlaxoSmithKline |
2008-02-04 | PHASE1 |
| NCT00627575 | COMPLETED | Epilepsy |
GlaxoSmithKline |
2008-02-04 | PHASE1 |
| NCT00917579 | COMPLETED | Hypercholesterolemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2008-07 | PHASE4 |
| NCT00610545 | COMPLETED | Vascular Surgery |
University of Campinas, Brazil |
2007-07 | PHASE4 |
| NCT00917579 | COMPLETED | Hypercholesterolemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2008-07 | PHASE4 |
| NCT00610545 | COMPLETED | Vascular Surgery |
University of Campinas, Brazil |
2007-07 | PHASE4 |
| NCT00496730 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2007-07 | PHASE3 |
| NCT00362934 | COMPLETED | Hyperlipidemia |
Solvay Pharmaceuticals |
2006-10 | PHASE3 |
| NCT00701883 | COMPLETED | Hyperlipidemia |
Gilead Sciences |
2007-08 | PHASE2 |
| NCT00496730 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2007-07 | PHASE3 |
| NCT00362934 | COMPLETED | Hyperlipidemia |
Solvay Pharmaceuticals |
2006-10 | PHASE3 |
| NCT00701883 | COMPLETED | Hyperlipidemia |
Gilead Sciences |
2007-08 | PHASE2 |
| NCT00716846 | COMPLETED | Healthy Volunteers |
Hamamatsu University |
2006-06 | |
| NCT00505336 | COMPLETED | Diastolic Heart Failure |
St Vincent's University Hospital, Ireland |
2006-04 | |
| NCT00716846 | COMPLETED | Healthy Volunteers |
Hamamatsu University |
2006-06 | |
| NCT00505336 | COMPLETED | Diastolic Heart Failure |
St Vincent's University Hospital, Ireland |
2006-04 | |
| NCT00367458 | COMPLETED | HIV |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-10-18 | PHASE2 |
| NCT00367458 | COMPLETED | HIV |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-10-18 | PHASE2 |
| NCT01062802 | COMPLETED | Abdominal Aortic Aneurysm |
University of Hull |
2005-01 | PHASE4 |
| NCT00395486 | COMPLETED | Metabolic Syndrome X |
AstraZeneca |
2006-09 | PHASE4 |
| NCT00585611 | TERMINATED | Diastolic Heart Failure |
University of Wisconsin, Madison |
2005-12 | |
| NCT00395486 | COMPLETED | Metabolic Syndrome X |
AstraZeneca |
2006-09 | PHASE4 |
| NCT00585611 | TERMINATED | Diastolic Heart Failure |
University of Wisconsin, Madison |
2005-12 | |
| NCT01062802 | COMPLETED | Abdominal Aortic Aneurysm |
University of Hull |
2005-01 | PHASE4 |
| NCT00540293 | COMPLETED | Dyslipidemias |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2007-10 | PHASE4 |
| NCT00540293 | COMPLETED | Dyslipidemias |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2007-10 | PHASE4 |
| NCT00678522 | COMPLETED | Healthy Subjects |
Regional Hospital Holstebro |
2007-09 | PHASE4 |
| NCT00678522 | COMPLETED | Healthy Subjects |
Regional Hospital Holstebro |
2007-09 | PHASE4 |
| NCT00344370 | COMPLETED | Type II Diabetes Mellitus; Dyslipidemia |
Kowa Research Europe |
2006-08 | PHASE3 |
| NCT00344370 | COMPLETED | Type II Diabetes Mellitus; Dyslipidemia |
Kowa Research Europe |
2006-08 | PHASE3 |
| NCT00412113 | COMPLETED | Dyslipidemia; Hypertension |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2007-01 | PHASE4 |
| NCT00530946 | COMPLETED | Hypertension; Hypercholesterolemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2007-09 | PHASE3 |
| NCT00412113 | COMPLETED | Dyslipidemia; Hypertension |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2007-01 | PHASE4 |
| NCT00530946 | COMPLETED | Hypertension; Hypercholesterolemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2007-09 | PHASE3 |
| NCT00770796 | COMPLETED | Contrast Induced Nephropathy |
Ospedale Misericordia e Dolce |
2006-04 | PHASE4 |
| NCT00300430 | COMPLETED | Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia |
Abbott |
2006-09 | PHASE3 |
| NCT00770796 | COMPLETED | Contrast Induced Nephropathy |
Ospedale Misericordia e Dolce |
2006-04 | PHASE4 |
| NCT00300430 | COMPLETED | Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia |
Abbott |
2006-09 | PHASE3 |
| NCT00494663 | TERMINATED | Type 2 Diabetes |
DiObex |
2007-07 | PHASE2 |
| NCT00494663 | TERMINATED | Type 2 Diabetes |
DiObex |
2007-07 | PHASE2 |
| NCT00427960 | TERMINATED | Hypercholesterolaemia |
AstraZeneca |
2006-12 | PHASE4 |
| NCT00465088 | COMPLETED | Hyperlipidemia; Mixed Dyslipidemia |
Abbott |
2007-04 | PHASE3 |
| NCT00427960 | TERMINATED | Hypercholesterolaemia |
AstraZeneca |
2006-12 | PHASE4 |
| NCT00276484 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2006-02 | PHASE3 |
| NCT00286312 | COMPLETED | Myocardial Infarction; Reperfusion Injury |
R&D Cardiologie |
2006-02 | PHASE4 |
| NCT00465088 | COMPLETED | Hyperlipidemia; Mixed Dyslipidemia |
Abbott |
2007-04 | PHASE3 |
| NCT00276484 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2006-02 | PHASE3 |
| NCT00504829 | COMPLETED | Dyslipidemia |
Veloxis Pharmaceuticals |
2007-07 | PHASE2 |
| NCT00286312 | COMPLETED | Myocardial Infarction; Reperfusion Injury |
R&D Cardiologie |
2006-02 | PHASE4 |
| NCT00504829 | COMPLETED | Dyslipidemia |
Veloxis Pharmaceuticals |
2007-07 | PHASE2 |
| NCT00974740 | TERMINATED | Type 1 Diabetes |
Profil Institut für Stoffwechselforschung GmbH |
2004-03 | PHASE1 |
| NCT00276458 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2006-02 | PHASE3 |
| NCT00276458 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2006-02 | PHASE3 |
| NCT00536887 | COMPLETED | Acute Myocardial Infarction |
Korea University Anam Hospital |
2005-07 | PHASE4 |
| NCT00536887 | COMPLETED | Acute Myocardial Infarction |
Korea University Anam Hospital |
2005-07 | PHASE4 |
| NCT00412841 | TERMINATED | Avascular Necrosis |
NYU Langone Health |
2002-11 | PHASE2 |
| NCT00974740 | TERMINATED | Type 1 Diabetes |
Profil Institut für Stoffwechselforschung GmbH |
2004-03 | PHASE1 |
| NCT00412841 | TERMINATED | Avascular Necrosis |
NYU Langone Health |
2002-11 | PHASE2 |
| NCT00359281 | COMPLETED | Healthy |
Aegerion Pharmaceuticals, Inc. |
2006-03 | PHASE2 |
| NCT00359281 | COMPLETED | Healthy |
Aegerion Pharmaceuticals, Inc. |
2006-03 | PHASE2 |
| NCT00166504 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2005-10 | PHASE4 |
| NCT00435045 | COMPLETED | Hypertriglyceridemia |
GlaxoSmithKline |
2007-02 | PHASE3 |
| NCT00435045 | COMPLETED | Hypertriglyceridemia |
GlaxoSmithKline |
2007-02 | PHASE3 |
| NCT00166504 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2005-10 | PHASE4 |
| NCT00157924 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2005-11 | PHASE4 |
| NCT00126048 | COMPLETED | Asthma |
University of Glasgow |
2005-07 | PHASE2; PHASE3 |
| NCT00157924 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2005-11 | PHASE4 |
| NCT00126048 | COMPLETED | Asthma |
University of Glasgow |
2005-07 | PHASE2; PHASE3 |
| NCT00072826 | COMPLETED | Sickle Cell Disease |
National Institutes of Health Clinical Center (CC) |
2003-11-04 | PHASE1 |
| NCT00072826 | COMPLETED | Sickle Cell Disease |
National Institutes of Health Clinical Center (CC) |
2003-11-04 | PHASE1 |
| NCT00214630 | COMPLETED | Acute Coronary Syndromes |
AstraZeneca |
2003-12 | PHASE3 |
| NCT00214630 | COMPLETED | Acute Coronary Syndromes |
AstraZeneca |
2003-12 | PHASE3 |
| NCT00652327 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2005-12 | PHASE4 |
| NCT00652327 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2005-12 | PHASE4 |
| NCT00132717 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2005-01-01 | PHASE3 |
| NCT00132717 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2005-01-01 | PHASE3 |
| NCT00134264 | TERMINATED | Coronary Disease; Diabetes Mellitus |
Pfizer |
2004-07 | PHASE3 |
| NCT00616187 | COMPLETED | Relapsing Remitting Multiple Sclerosis |
Charite University, Berlin, Germany |
2003-10 | PHASE2 |
| NCT00309751 | COMPLETED | Type II Diabetes Mellitus; Dyslipidemia |
Kowa Research Europe |
2005-12 | PHASE3 |
| NCT00134264 | TERMINATED | Coronary Disease; Diabetes Mellitus |
Pfizer |
2004-07 | PHASE3 |
| NCT00395603 | TERMINATED | Cardiovascular Diseases; Diabetes Mellitus |
Organon and Co |
2006-09 | PHASE3 |
| NCT00309751 | COMPLETED | Type II Diabetes Mellitus; Dyslipidemia |
Kowa Research Europe |
2005-12 | PHASE3 |
| NCT00395603 | TERMINATED | Cardiovascular Diseases; Diabetes Mellitus |
Organon and Co |
2006-09 | PHASE3 |
| NCT00616187 | COMPLETED | Relapsing Remitting Multiple Sclerosis |
Charite University, Berlin, Germany |
2003-10 | PHASE2 |
| NCT00487994 | COMPLETED | Dyslipidemia |
Takeda |
2004-11 | PHASE3 |
| NCT00487994 | COMPLETED | Dyslipidemia |
Takeda |
2004-11 | PHASE3 |
| NCT00751907 | COMPLETED | Alzheimer's Disease |
University of Wisconsin, Madison |
2006-06 | PHASE2 |
| NCT00751907 | COMPLETED | Alzheimer's Disease |
University of Wisconsin, Madison |
2006-06 | PHASE2 |
| NCT00134550 | COMPLETED | Foot Ulcer; Diabetes |
Asker & Baerum Hospital |
2005-02 | PHASE2 |
| NCT00134550 | COMPLETED | Foot Ulcer; Diabetes |
Asker & Baerum Hospital |
2005-02 | PHASE2 |
| NCT01187992 | TERMINATED | Acute Coronary Syndrome; Coronary Artery Disease |
San Filippo Neri General Hospital |
2003-09 | PHASE3 |
| NCT01187992 | TERMINATED | Acute Coronary Syndrome; Coronary Artery Disease |
San Filippo Neri General Hospital |
2003-09 | PHASE3 |
| NCT00166530 | COMPLETED | Atherosclerosis |
Organon and Co |
2005-11 | PHASE4 |
| NCT00166530 | COMPLETED | Atherosclerosis |
Organon and Co |
2005-11 | PHASE4 |
| NCT00300469 | COMPLETED | Mixed Dyslipidemia; Coronary Heart Disease; Dyslipidemia |
Abbott |
2006-03 | PHASE3 |
| NCT00300469 | COMPLETED | Mixed Dyslipidemia; Coronary Heart Disease; Dyslipidemia |
Abbott |
2006-03 | PHASE3 |
| NCT00411190 | COMPLETED | Osteoarthritis |
GlaxoSmithKline |
2006-10-19 | PHASE1 |
| NCT00411190 | COMPLETED | Osteoarthritis |
GlaxoSmithKline |
2006-10-19 | PHASE1 |
| NCT00355251 | TERMINATED | HIV Infections |
Germans Trias i Pujol Hospital |
2006-07 | PHASE4 |
| NCT00267280 | TERMINATED | Hyperlipidemia; Dyslipidemia; Hypercholesterolemia |
Pfizer |
2006-01 | PHASE3 |
| NCT00355251 | TERMINATED | HIV Infections |
Germans Trias i Pujol Hospital |
2006-07 | PHASE4 |
| NCT00267280 | TERMINATED | Hyperlipidemia; Dyslipidemia; Hypercholesterolemia |
Pfizer |
2006-01 | PHASE3 |
| NCT00770575 | COMPLETED | Cardiovascular Diseases |
Takeda |
2005-06 | PHASE2 |
| NCT00319449 | COMPLETED | Hypercholesterolemia; Coronary Arteriosclerosis |
Organon and Co |
2005-09 | PHASE4 |
| NCT00319449 | COMPLETED | Hypercholesterolemia; Coronary Arteriosclerosis |
Organon and Co |
2005-09 | PHASE4 |
| NCT00202904 | COMPLETED | Hypercholesterolemia; Coronary Heart Disease |
Organon and Co |
2005-05 | PHASE4 |
| NCT00770575 | COMPLETED | Cardiovascular Diseases |
Takeda |
2005-06 | PHASE2 |
| NCT00202904 | COMPLETED | Hypercholesterolemia; Coronary Heart Disease |
Organon and Co |
2005-05 | PHASE4 |
| NCT00138762 | COMPLETED | Hyperlipidemia |
Pfizer |
2004-07 | PHASE3 |
| NCT00138762 | COMPLETED | Hyperlipidemia |
Pfizer |
2004-07 | PHASE3 |
| NCT00194402 | COMPLETED | Dyslipidemia |
University of Washington |
2003-08 | PHASE4 |
| NCT00194402 | COMPLETED | Dyslipidemia |
University of Washington |
2003-08 | PHASE4 |
| NCT00110435 | COMPLETED | Type 2 Diabetes Mellitus; Hypercholesterolemia |
Organon and Co |
2005-05 | PHASE3 |
| NCT00110435 | COMPLETED | Type 2 Diabetes Mellitus; Hypercholesterolemia |
Organon and Co |
2005-05 | PHASE3 |
| NCT00241488 | COMPLETED | Hypercholesterolemia |
AstraZeneca |
2003-06 | PHASE3 |
| NCT00241488 | COMPLETED | Hypercholesterolemia |
AstraZeneca |
2003-06 | PHASE3 |
| NCT00239330 | COMPLETED | Hypercholesteremia |
AstraZeneca |
2003-06 | PHASE3 |
| NCT00239330 | COMPLETED | Hypercholesteremia |
AstraZeneca |
2003-06 | PHASE3 |
| NCT00345202 | COMPLETED | Healthy |
Regional Hospital Holstebro |
2004-09 | PHASE4 |
| NCT00345202 | COMPLETED | Healthy |
Regional Hospital Holstebro |
2004-09 | PHASE4 |
| NCT00651404 | COMPLETED | Hypercholesterolemia; Atherosclerosis |
Organon and Co |
2004-01 | PHASE3 |
| NCT00651404 | COMPLETED | Hypercholesterolemia; Atherosclerosis |
Organon and Co |
2004-01 | PHASE3 |
| NCT00090168 | COMPLETED | Hypercholesterolemia; Atherosclerotic Disease; Coronary Disease |
Organon and Co |
2004-01-27 | PHASE3 |
| NCT00090168 | COMPLETED | Hypercholesterolemia; Atherosclerotic Disease; Coronary Disease |
Organon and Co |
2004-01-27 | PHASE3 |
| NCT03882996 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2000-10-06 | PHASE3 |
| NCT03882996 | COMPLETED | Hypercholesterolemia |
Organon and Co |
2000-10-06 | PHASE3 |
| NCT02587416 | COMPLETED | Hypercholesteremia |
NeuroBo Pharmaceuticals Inc. |
2002-11 | PHASE1 |
| NCT02587416 | COMPLETED | Hypercholesteremia |
NeuroBo Pharmaceuticals Inc. |
2002-11 | PHASE1 |
| NCT00632840 | COMPLETED | Obesity; Lipid Disorders; Hypertriglyceridemia; Cardiovascular Disease |
The University of Western Australia |
2001-06 | PHASE4 |
| NCT00632840 | COMPLETED | Obesity; Lipid Disorders; Hypertriglyceridemia; Cardiovascular Disease |
The University of Western Australia |
2001-06 | PHASE4 |
| NCT03884452 | COMPLETED | Familial Hypercholesterolemia |
Organon and Co |
2000-05-03 | PHASE3 |
| NCT03884452 | COMPLETED | Familial Hypercholesterolemia |
Organon and Co |
2000-05-03 | PHASE3 |
| NCT00150384 | COMPLETED | Hypertension; Dyslipidemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2004-07 | PHASE4 |
| NCT00115830 | COMPLETED | Atherosclerosis |
Brigham and Women's Hospital |
2004-12 | PHASE3 |
| NCT00079638 | COMPLETED | Dyslipidemia; Coronary Heart Disease; Atherosclerosis; Stroke; Diabetes |
Kos Pharmaceuticals |
2004-04 | PHASE4 |
| NCT00457340 | COMPLETED | Arrhythmia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2000-02 | PHASE4 |
| NCT00522158 | COMPLETED | Type 2 Diabetes Mellitus; Cardiovascular Disease; LDL Cholesterol; Cognition |
Baskent University |
PHASE4 | |
| NCT00151502 | COMPLETED | Alzheimer's Disease |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2002-11 | PHASE3 |
| NCT00267267 | TERMINATED | Hyperlipidemia; Dyslipidemia |
Pfizer |
2006-01 | PHASE3 |
| NCT00164086 | UNKNOWN | Myeloma |
Bayside Health |
PHASE1 | |
| NCT00124397 | COMPLETED | Type 2 Diabetes Mellitus |
University of Southern Denmark |
2001-07 | PHASE4 |
| NCT00388596 | COMPLETED | Osteoporosis |
GlaxoSmithKline |
2006-10 | PHASE1 |
| NCT00201552 | UNKNOWN | Paroxysmal Atrial Fibrillation |
National Taiwan University Hospital |
||
| NCT00380939 | COMPLETED | Coronary Arteriosclerosis |
Pfizer |
1999-04 | PHASE4 |
| NCT00163202 | COMPLETED | Coronary Arteriosclerosis; Hypercholesterolemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2002-06 | PHASE4 |
| NCT00024531 | COMPLETED | Alzheimer Disease |
Institute for the Study of Aging (ISOA) |
2000-10 | PHASE2 |
| NCT00136942 | COMPLETED | Hyperlipidemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2005-04 | PHASE3 |
| NCT00653588 | COMPLETED | Hypercholesterolemia; Coronary Heart Disease |
AstraZeneca |
2003-04 | PHASE3 |
| NCT00115817 | COMPLETED | Atherosclerosis |
Brigham and Women's Hospital |
2005-06 | PHASE3 |
| NCT00432354 | UNKNOWN | Systemic Lupus Erythematosus |
Buddhist Tzu Chi General Hospital |
2007-03 | PHASE2; PHASE3 |
| NCT00335699 | COMPLETED | Hypercholesterolemia |
AstraZeneca |
2005-08 | PHASE4 |
| NCT00151502 | COMPLETED | Alzheimer's Disease |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2002-11 | PHASE3 |
| NCT00497016 | COMPLETED | Hypertension |
Radboud University Medical Center |
2007-05 | |
| NCT00164086 | UNKNOWN | Myeloma |
Bayside Health |
PHASE1 | |
| NCT00120133 | COMPLETED | Osteoporosis |
Children's Mercy Hospital Kansas City |
2004-12 | |
| NCT00124397 | COMPLETED | Type 2 Diabetes Mellitus |
University of Southern Denmark |
2001-07 | PHASE4 |
| NCT00388596 | COMPLETED | Osteoporosis |
GlaxoSmithKline |
2006-10 | PHASE1 |
| NCT00201552 | UNKNOWN | Paroxysmal Atrial Fibrillation |
National Taiwan University Hospital |
||
| NCT00103974 | COMPLETED | Multiple Sclerosis |
Bayhill Therapeutics |
2004-07 | PHASE1 |
| NCT00654407 | COMPLETED | Hypercholesterolemia |
AstraZeneca |
2001-11 | PHASE3 |
| NCT00163202 | COMPLETED | Coronary Arteriosclerosis; Hypercholesterolemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2002-06 | PHASE4 |
| NCT00327691 | COMPLETED | Cardiovascular Disease; Cerebrovascular Accident; Coronary Heart Disease |
Pfizer |
1998-04 | PHASE4 |
| NCT00653588 | COMPLETED | Hypercholesterolemia; Coronary Heart Disease |
AstraZeneca |
2003-04 | PHASE3 |
| NCT00115817 | COMPLETED | Atherosclerosis |
Brigham and Women's Hospital |
2005-06 | PHASE3 |
| NCT00432354 | UNKNOWN | Systemic Lupus Erythematosus |
Buddhist Tzu Chi General Hospital |
2007-03 | PHASE2; PHASE3 |
| NCT00335699 | COMPLETED | Hypercholesterolemia |
AstraZeneca |
2005-08 | PHASE4 |
| NCT00497016 | COMPLETED | Hypertension |
Radboud University Medical Center |
2007-05 | |
| NCT00267254 | COMPLETED | Hyperlipidemia; Dyslipidemia; Hypercholesterolemia |
Pfizer |
2006-01 | PHASE3 |
| NCT00139061 | COMPLETED | Hyperlipidemia |
Pfizer |
2005-03 | PHASE3 |
| NCT01053065 | COMPLETED | Symptomatic Carotid Stenosis; Hypercholesterolemia; Indication for Carotid Endarterectomy |
University of Padova |
||
| NCT00120133 | COMPLETED | Osteoporosis |
Children's Mercy Hospital Kansas City |
2004-12 | |
| NCT00134173 | COMPLETED | Coronary Disease; Coronary Arteriosclerosis; Hyperlipidemia |
Pfizer |
2003-10 | PHASE3 |
| NCT00000941 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00103974 | COMPLETED | Multiple Sclerosis |
Bayhill Therapeutics |
2004-07 | PHASE1 |
| NCT00653965 | COMPLETED | Hypercholesterolemia; Dyslipidaemia |
AstraZeneca |
2003-05 | PHASE3 |
| NCT00654407 | COMPLETED | Hypercholesterolemia |
AstraZeneca |
2001-11 | PHASE3 |
| NCT00134498 | COMPLETED | Hypertriglyceridemia; Hyperlipoproteinemia Type IV |
Pfizer |
2005-02 | PHASE3 |
| NCT00433823 | UNKNOWN | Coronary Heart Disease; Diabetes Mellitus; Non-Coronary Atherosclerotic Disease; Hypercholesterolemia |
Abant Izzet Baysal University |
2007-01 | PHASE4 |
| NCT00327691 | COMPLETED | Cardiovascular Disease; Cerebrovascular Accident; Coronary Heart Disease |
Pfizer |
1998-04 | PHASE4 |
| NCT00654537 | COMPLETED | Hypercholesterolemia |
AstraZeneca |
2001-04 | PHASE3 |
| NCT00572312 | COMPLETED | Chronic Kidney Disease; Proteinuria |
Medical University of Gdansk |
2005-02 | |
| NCT00004564 | UNKNOWN | Hypercholesterolemia; Thrombosis |
National Center for Research Resources (NCRR) |
||
| NCT00403533 | COMPLETED | Hepatitis C |
Massachusetts General Hospital |
2006-02 | PHASE2 |
| NCT00408382 | COMPLETED | Hypercholesteremia; Coronary Artery Disease |
Astellas Pharma Inc |
PHASE4 | |
| NCT00654485 | COMPLETED | Metabolic Syndrome |
AstraZeneca |
2002-05 | PHASE3 |
| NCT00267254 | COMPLETED | Hyperlipidemia; Dyslipidemia; Hypercholesterolemia |
Pfizer |
2006-01 | PHASE3 |
| NCT00139061 | COMPLETED | Hyperlipidemia |
Pfizer |
2005-03 | PHASE3 |
| NCT01053065 | COMPLETED | Symptomatic Carotid Stenosis; Hypercholesterolemia; Indication for Carotid Endarterectomy |
University of Padova |
||
| NCT00449410 | COMPLETED | Atrial Fibrillation; Neuropsychology; Magnetic Resonance Imaging; Inflammation; Hemostasis |
Radboud University Medical Center |
2005-05 | PHASE4 |
| NCT00147602 | COMPLETED | Cardiovascular Disease |
Pfizer |
1998-11 | PHASE4 |
| NCT00134173 | COMPLETED | Coronary Disease; Coronary Arteriosclerosis; Hyperlipidemia |
Pfizer |
2003-10 | PHASE3 |
| NCT00150371 | COMPLETED | Hypercholesterolemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2004-06 | PHASE3 |
| NCT00000941 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00653965 | COMPLETED | Hypercholesterolemia; Dyslipidaemia |
AstraZeneca |
2003-05 | PHASE3 |
| NCT00150384 | COMPLETED | Hypertension; Dyslipidemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2004-07 | PHASE4 |
| NCT00134498 | COMPLETED | Hypertriglyceridemia; Hyperlipoproteinemia Type IV |
Pfizer |
2005-02 | PHASE3 |
| NCT00115830 | COMPLETED | Atherosclerosis |
Brigham and Women's Hospital |
2004-12 | PHASE3 |
| NCT00079638 | COMPLETED | Dyslipidemia; Coronary Heart Disease; Atherosclerosis; Stroke; Diabetes |
Kos Pharmaceuticals |
2004-04 | PHASE4 |
| NCT00433823 | UNKNOWN | Coronary Heart Disease; Diabetes Mellitus; Non-Coronary Atherosclerotic Disease; Hypercholesterolemia |
Abant Izzet Baysal University |
2007-01 | PHASE4 |
| NCT00457340 | COMPLETED | Arrhythmia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2000-02 | PHASE4 |
| NCT00522158 | COMPLETED | Type 2 Diabetes Mellitus; Cardiovascular Disease; LDL Cholesterol; Cognition |
Baskent University |
PHASE4 | |
| NCT00654537 | COMPLETED | Hypercholesterolemia |
AstraZeneca |
2001-04 | PHASE3 |
| NCT00572312 | COMPLETED | Chronic Kidney Disease; Proteinuria |
Medical University of Gdansk |
2005-02 | |
| NCT00004564 | UNKNOWN | Hypercholesterolemia; Thrombosis |
National Center for Research Resources (NCRR) |
||
| NCT00403533 | COMPLETED | Hepatitis C |
Massachusetts General Hospital |
2006-02 | PHASE2 |
| NCT00267267 | TERMINATED | Hyperlipidemia; Dyslipidemia |
Pfizer |
2006-01 | PHASE3 |
| NCT00408382 | COMPLETED | Hypercholesteremia; Coronary Artery Disease |
Astellas Pharma Inc |
PHASE4 | |
| NCT00654485 | COMPLETED | Metabolic Syndrome |
AstraZeneca |
2002-05 | PHASE3 |
| NCT00380939 | COMPLETED | Coronary Arteriosclerosis |
Pfizer |
1999-04 | PHASE4 |
| NCT00449410 | COMPLETED | Atrial Fibrillation; Neuropsychology; Magnetic Resonance Imaging; Inflammation; Hemostasis |
Radboud University Medical Center |
2005-05 | PHASE4 |
| NCT00147602 | COMPLETED | Cardiovascular Disease |
Pfizer |
1998-11 | PHASE4 |
| NCT00024531 | COMPLETED | Alzheimer Disease |
Institute for the Study of Aging (ISOA) |
2000-10 | PHASE2 |
| NCT00150371 | COMPLETED | Hypercholesterolemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2004-06 | PHASE3 |
| NCT00136942 | COMPLETED | Hyperlipidemia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2005-04 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-05-06)
Check the
Atorvastatin calcium hydrate
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Atorvastatin calcium hydrate Solubility in DMSO
- Atorvastatin calcium hydrate Stock Solution
- Atorvastatin calcium hydrate Storage
- Atorvastatin calcium hydrate Stability
- Atorvastatin calcium hydrate Molecular Weight
- Atorvastatin calcium hydrate CAS Number
- Atorvastatin calcium hydrate Chemical Structure (2D and 3D)
- Atorvastatin calcium hydrate SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.